Liigeskudede molekulaarsed markerid põlveliigese varase osteoartroosi korral: rahvastikupõhine longitudinaalne uuring keskealistel isikutel by Kumm, Jaanika


















Molecular markers  
of articular tissues in early knee osteoarthritis:  
a population-based longitudinal study  


















Department of Internal Medicine, University of Tartu, Estonia 
 
This dissertation is accepted for the commencement of the degree of Doctor of 
Philosophy on 6th of July 2012 by the Council of the Faculty of Medicine, Uni-
versity of Tartu, Estonia.  
 
Supervisors:  Agu Tamm, MD, DMSci, Professor 
                          Department of Internal Medicine, University of Tartu, Estonia 
 
                          Kalervo Väänänen MD, PhD, Professor 
Department of Cell Biology and Anatomy,  
Institute of Biomedicine,  University of Turku, Finland 
 
Reviewers:      Riina Kallikorm MD, PhD, Associate Professor 
                         Department of Internal Medicine, University of Tartu, Estonia 
 
                          Kai Kisand MD, PhD 
Institute of General and Molecular Pathology,  
University of Tartu, Estonia 
 
Opponent:       Ingemar Petersson MD, PhD, Professor 
                     Departments of Orthopedics and Rheumatology,  
Skåne University Hospital, Lund, Sweden 
 
Commencement: 19th of October, 2012 
 





ISBN 978–9949–32–106–3 (print)  




www.tyk.ee   
Copyright: Jaanika Kumm, 2012 
University of Tartu Press 
Order No. 416 
5 
TABLE OF CONTENTS 
 
1.  LIST OF PUBLICATIONS  .....................................................................  7 
2.  ABBREVIATIONS  ..................................................................................  8 
3.  INTRODUCTION  ....................................................................................  9 
4.  REVIEW OF THE LITERATURE  ..........................................................  11 
4.1. Osteoarthritis  .....................................................................................  11 
4.1.1. Definition and the new concept of OA  ...................................  11 
4.1.2. OA risk factors and pathogenesis  ...........................................  11 
4.1.2.1.  Risk factors for OA  ..................................................  11 
4.1.2.2.  OA pathogenesis – articular cartilage  ......................  12 
4.1.2.3.  OA pathogenesis – osteophytes and changes in 
subchondral bone  .....................................................  12 
4.1.2.4.  The role of inflammation in OA  ...............................  14 
4.1.3. Clinical criteria of knee OA  ....................................................  14 
4.1.4. Imaging methods for diagnosing knee OA  .............................  15 
4.1.5. The prevalence and progression  of radiographic knee OA in 
middle-aged subjects  ..............................................................  17 
4.2.  Molecular markers of articular tissues in OA  ...................................  17 
4.2.1. Molecular markers of cartilage turnover  ................................  20 
4.2.2. Molecular markers of bone turnover  ......................................  21 
4.3.  Molecular markers of joint tissue metabolism  in incident and/or 
progressive knee OA  ........................................................................  23 
4.3.1. Cartilage markers in incident and/or  progressive knee OA  ...  23 
4.3.2. Bone markers in incident and/or progressive knee OA  ..........  24 
5. AIMS OF THE STUDY  ............................................................................  26 
6. MATERIALS AND METHODS  ..............................................................  27 
6.1.  Study subjects  ...................................................................................  27 
6.2.  Standardized radiographic investigation  ..........................................  29 
6.3.  Ultrasonographic examination  ..........................................................  29 
6.4.  Laboratory investigation  ...................................................................  30 
6.5.  Statistical analysis  ............................................................................  31 
7. RESULTS  ..................................................................................................  33 
7.1.  Serum COMP and urinary MidOC – specifications  for their usage 
as molecular markers of joint tissue metabolism (Papers I–II)  ........  33 
7.1.1. Serum COMP – a marker reflecting metabolic changes in 
several articular tissues  ...........................................................  33 
7.1.2. Urinary MidOC – a novel marker of bone resorption  ............  34 
7.2.  Results of radiographic investigations  ..............................................  35 
7.2.1. The prevalence of radiographic knee OA (Paper III)  .............  35 
7.2.2. Radiographic knee OA progression over six years (Paper III)  36 
7.2.2.1.  Radiographic knee OA progression  in two 
consecutive three-year follow-up periods  ................  36 
6 
7.2.2.2.  Individual pattern and types  of knee OA 
progression over six years  ........................................  37 
7.3.  Effect of age, gender, BMI and menopausal status on serum and 
urinary values of biomarkers  ............................................................  38 
7.4.  Associations between joint tissue biomarkers and radiographic 
knee OA at three different time-points (Paper V)  ............................  39 
7.5.  Associations between biomarkers and ultrasonographic features in 
OA (Paper IV)  ..................................................................................  40 
7.6.  Associations between cartilage and bone biomarkers and 
radiographic knee OA progression (Papers V–VI)  ...........................  43 
7.6.1. The diagnostic and prognostic value of cartilage markers in 
radiographic knee OA progression (Paper V)  ........................  43 
7.6.1.1.  Cartilage markers over the six-year follow-up if 
knee OA progression was expressed by global OA 
grades  .......................................................................  43 
7.6.1.2.  The diagnostic and prognostic values of the 
cartilage markers if radiographic OA progression 
was expressed separately by osteophytes and JSN 
over two three-year periods  .....................................  44 
7.6.1.3.  The diagnostic and prognostic value of the cartilage 
markers if distinct forms of progressive OA were 
differentiated  ............................................................  45 
7.6.2. The diagnostic and prognostic value of bone markers in 
radiographic knee OA progression (Paper VI)  .......................  46 
7.6.2.1.  Bone markers over a six-year follow-up if knee OA 
progression was expressed by global OA grades  .....  46 
7.6.2.2.  The diagnostic and prognostic values of the bone 
markers  if radiographic OA progression was 
expressed separately by osteophytes and JSN  .........  47 
7.6.2.3.  The diagnostic and prognostic value of the bone 
markers if distinct forms of progressive OA were 
differentiated  ............................................................  47 
7.7.  Simultaneous assessment of the associations between cartilage and 
bone biomarkers and knee OA progression  ......................................  49 
8. DISCUSSION  ...........................................................................................  52 
9. SUMMARY  ..............................................................................................  63 
10. CONCLUSIONS  .....................................................................................  65 
11. SUMMARY IN ESTONIAN  ..................................................................  67 
12. ACKNOWLEDGEMENTS  ....................................................................  71 
REFERENCES  ..............................................................................................  73 
PUBLICATIONS  ..........................................................................................  83 
CURRICULUM VITAE  ...............................................................................  147 
7 
1. LIST OF PUBLICATIONS 
 
I.     Kumm J, Tamm A, Veske K, Lintrop M, Tamm A. Associations between 
cartilage oligomeric matrix protein and several articular tissues in early 
knee joint osteoarthritis. Rheumatology 2006; 45(10):1308–1309.  
 
II.   Kumm J, Ivaska KK, Rohtla K, Väänänen K, Tamm A. Urinary osteocalcin 
and other markers of bone metabolism: the effect of risedronate therapy. 
Scand J Clin Lab Invest 2008; 68(6):459–63 
 
III.  Kumm J, Tamm A, Lintrop M, Tamm A. The prevalence and progression 
of radiographic knee osteoarthritis over 6 years in a population-based 
cohort of middle-aged subjects. Rheumatol Int 2011, Nov 16; doi: 10.1007/ 
s00296–011–2221–3 
 
IV. Kumm J, Tamm A, Lintrop M, Tamm A. Association between ultrasono-
graphic findings and bone/cartilage biomarkers in patients with early-stage 
knee osteoarthritis. Calcif Tissue Int 2009; 85: 514–522 
 
V.   Kumm J, Tamm A, Lintrop M, Tamm A. The value of cartilage biomarkers 
in progressive knee osteoarthritis: cross-sectional and 6-year follow-up 
study in middle-aged subjects. Rheumatol Int 2012, Jul 21; doi: 10.1007/ 
s00296–012–463–8  
 
VI.  Kumm J, Tamm A, Lintrop M, Tamm A. Diagnostic and prognostic value 
of bone biomarkers in progressive knee osteoarthritis: a 6-year follow-up 




Jaanika Kumm was involved in the study planning, subject recruitment, obtain-
ment of questionnaire data, collection of serum and urinary samples and radio-
graphic data for all the papers. She performed laboratory measurements, 















BMI          body mass index 
JSN          joint space narrowing 
JSW          joint space width 
KL            Kellgren-Lawrence grading system  
MMP        matrix metalloproteinase 
MRI          magnetic resonance imaging 
OA            osteoarthritis 
Oph           osteophytes 
PF             patellofemoral 
ROI           region of interest 
sCOMP     serum cartilage oligmeric matrix protein 
sCTx-I       serum C-terminal cross-linked telopeptides of type I collagen 
sOC           serum osteocalcin 
sPINP        serum procollagen type I amino-terminal propeptide 
sPIIANP    serum type II A procollagen amino-terminal propeptide 
TF              tibiofemoral 
uCTx-II     urinary C-telopeptide fragments of type II collagen 
uMidOC    urinary midfragments of osteocalcin 




























Osteoarthritis (OA) is the most common form of arthritis and is still one of the 
few chronic diseases of the elderly for which there is little, if any, effective 
treatment [1]. It accounts for more mobility disability in the elderly than any 
other disease. The prevalence of symptomatic knee OA has ranged in different 
studies from 1.6–9.4% of adults and 10–15% of the elderly [2–3]. Since in-
cidence and prevalence increase with age, longer life expectancy suggests even 
further increase in OA in the future [1].  
OA has turned out to be a multifaceted and far more complex disease than 
initially believed. Nowadays, it is increasingly recognized that OA is a disease 
of the whole joint that affects all articular structures, including articular 
cartilage, subchondral bone, synovium, tendons, ligaments and menisci [4]. So 
far, the role of bone and articular soft tissues in the pathophysiology of OA has 
been widely overlooked. It is also not clear in whom the disease is likely to 
progress. It is assumed that the course of OA may not be constant but change 
over time. As the vast majority of studies on OA have been conducted on 
patients who have already reached end-stage disease, there is a significant lack 
of knowledge concerning the early phases of OA. 
It is logical that subtle biochemical changes in articular cartilage and other 
joint tissues precede any macroscopic or radiographic evidence of joint 
destruction. Therefore, in recent years, an emphasis has been placed on deve-
loping serum and urinary molecular markers originating from different joint 
tissues, which would make it possible to evaluate the presence of OA metabolic 
changes during the earliest phases of the disease. These alterations are complex, 
as these involve not only joint tissue degradation but also the synthetic side of 
metabolism. In order to achieve a systematic overview of the pre-radiographic 
course of knee OA, it is necessary to assess biomarkers originating from diffe-
rent articular tissues, both cross-sectionally and longitudinally, in subjects much 
younger than those investigated previously, on a routine basis. This approach 
would make it possible to evaluate the diagnostic and potential predictive value 
of biomarkers for progressive OA. 
The current gold standard for diagnosing OA and its progression is still plain 
radiography. Indeed, cartilage loss can be indirectly quantified from radio-
graphic measurements of radiolucent joint space width (JSW). However, joint 
space narrowing (JSN) represents a late-stage indicator of already advanced 
cartilage destruction [5]. The importance of osteophytosis as an earlier radio-
graphic sign of knee OA has been underestimated. Just recently, it was stated 
that as JSN and osteophytes represent different OA pathophysiology they 
should ideally be looked at individually [6]. Ultrasonography serves as an 
excellent method for the examination of articular soft tissues. However, the 
method has not yet been entirely standardized for its usage in OA. 
Thus, the investigation of early-stage knee OA is not possible based on 
radiological methods alone, but requires a multifaceted diagnostic approach, 
including serum and urinary biomarkers originating from different joint tissues.  
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The globally increasing prevalence of OA calls for more detailed knowledge 
of the early phases of the disease. The investigation of OA pre-radiographic 
phases is utterly dependent on biomarkers as new diagnostic and/or prognostic 











4.1.1. Definition and the new concept of OA 
OA was long considered a degenerative disease, the inevitable accompaniment 
of ageing, with “wear and tear” as the principle pathogenetic mechanism. How-
ever, in 1984, Kiss et al. declared that OA was neither a disease of ageing nor 
an inevitable consequence of the ageing of joints [7]. Indeed, according to the 
new concept, OA is now viewed as a metabolically active, dynamic process that 
may be triggered by a variety of biochemical and mechanical insults that 
destabilize the normal coupling of degradation and synthesis of all articular 
tissues, especially cartilage chondrocytes and the extracellular matrix [8]. Since 
1994, OA has been defined as a group of overlapping distinct diseases, which 
may have different etiologies but similar biological, morphologic, and clinical 
outcomes. The disease process not only affects articular cartilage, but involves 
the entire joint, including the subchondral bone, ligaments, capsule, synovial 
membrane and periarticular muscles [8].  
The OA disease process is now considered a continuum, beginning with an 
inciting event, such as genetic variation or injury, progressing through mole-
cular, pre-radiographic and radiographic stages, and culminating in end-stage 
disease [9].  
 
 
4.1.2. OA risk factors and pathogenesis 
4.1.2.1. Risk factors for OA 
Genetic predisposition 
Twin studies have demonstrated that the hereditary component of knee OA may 
be on the order of 50% to 65% [10–11].  
 
Gender 
There is a marked increase in the prevalence of knee OA among women after 
the age of 50. The cause of this increase has been ascribed to an insufficiency of 
estrogen, which in normal conditions is related to the up-regulation of proteo-
glycan synthesis through its receptors on chondrocytes [12].  
 
Age 
Age-related morphologic changes in articular cartilage are due to a decrease in 
chondrocytes' ability to maintain and repair tissue as these cells undergo age-
related decreases in mitotic and synthetic activity and exhibit decreased 
responsiveness to anabolic growth factors [13]. Age also appears to be an inde-
pendent factor that predisposes chondrocytes to apoptosis, because the expres-




An increase in excessive load across knee joints is an important factor leading 
to cartilage breakdown. The majority of obese patients exhibit various defor-
mities, which result in increased joint reactive forces in the medial compartment 
of the knee, thereby accelerating the degenerative process [16–17]. Emerging 
data show a crucial role for adipocytes in regulation of cells in bone, cartilage 
and soft tissues of the joint. It has been demonstrated that the adipocyte-derived 
factor interleukine-6 is procatabolic for chondrocytes [16]. 
It is clear that in any OA study the above-mentioned risk factors should be 
taken into consideration as important confounding factors. 
 
 
4.1.2.2. OA pathogenesis – articular cartilage 
Articular cartilage is comprised largely of an extracellular matrix synthesized 
by chondrocytes – the only cell type in cartilage [18]. Chondrocytes control the 
local environment of the cartilage extracellular matrix by performing both 
anabolic and catabolic activities [19]. The major part of the articular extra-
cellular matrix is composed of collagen type II (60–70% of dry weight) and 
proteoglycans (10% of dry weight), of which aggrecan is the most abundant 
[20]. Other types of collagens are present in only minor amounts.  
In OA, chondrocytes are activated by mechanical events (trauma) or genetic 
assault (mutation of a matrix molecule), to which they respond by increased 
metabolic activity, trying to repair the damaged matrix [21]. Although cartilage 
has a poor intrinsic reparative potential, there is an increase in aggrecan turn-
over, type II collagen synthesis and renewed chondrocyte proliferation [22]. 
This hyperanabolism has become a hallmark of OA cartilage – an attempt to 
repair the tissue that eventually fails [21]. These events finally end when the 
balance of catabolic events outstrips the anabolic events [21]. According to 
previous studies, temporally the first event in OA related cartilage degradation 
is the loss of aggrecan, which occurs prior to the breakdown of type II collagen 
[23–24]. The loss of cartilage matrix is mediated by proteolytic enzymes 
secreted by the chondrocytes and synoviocytes, including collagenases, the 
matrix metalloproteases (MMP`s) and the cysteine proteases [25–26]. Among 
them MMPs, especially MMP-13, play a central role [27–29]. There are, how-
ever, multiple pathways of chondrocyte triggering, which finally result in a 
common pathway of MMP-mediated collagen type II breakdown. 
 
 
4.1.2.3. OA pathogenesis – osteophytes and changes in subchondral bone 
Although it is now widely accepted that OA is a disease that can be initiated in 
any joint tissue, among them subchondral bone, research has long been focused 
predominantly on cartilage changes. However, there is evidence that re-
modelling of the bone-cartilage interface occurs early in the course of OA [30–
32]. Moreover, even two decades ago it was suggested that changes in bone 
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might even precede changes in cartilage and might be responsible for the initial 
pathophysiological events in OA [30; 33]. 
Generally, in OA, the changes in periarticular bone are characterized by 
osteophyte formation and a sequence of subchondral changes finally leading to 
sclerosis [34].   
Osteophytes are osteo-cartilaginous metaplastic tissues, protrusions of new 
cartilage which subsequently ossify, forming mostly at the margins of OA joints 
[35]. The cells that form osteophytes are considered to be mesenhymal stem 
cells residing in the periosteum [36].  Based on immunohistochemistry and in 
situ hybridization studies, the formation of osteophytes has been divided into 
five stages [35]:  
Stage 0: Mesenchymal fibroblast-like cells in periosteal or synovial mesen-
hymal tissue produce a connective tissue consisting mainly of collagen types I 
and VI. 
Stage I: Early chondrophyte, which is characterized by initial chondrometa-
plastic areas of deeper cell layers adjacent to the bone. Chondrogenic differen-
tiation is detectable by the appearance of an extracellular matrix containing 
aggrecan and collagen type IIA.  
Stage II: Fibrocartilage/chondrophyte, which is described as a structure with 
components of fibrous and cartilaginous tissue observed in parallel.  
Stage III: Early osteophyte, consisting of aggrecan, collagen type II and 
chondrocytes. In this phase, active endochondral bone formation is evident with 
osteoblastic synthesis of collagen type I. 
Stage IV: Mature osteophyte with extended ossification in the central core, 
although the predominant tissue is still hyaline cartilage. 
The actual role of osteophytes during the process of OA is still unknown. 
They seem to be a way of compensating for instability but, apparently, they can 
be a side effect of elevated levels of growth factors [36]. This hypothesis is 
supported by the fact that osteophytes are usually found in non-weight bearing 
areas; therefore, their mechanical stability and biological benefit are question-
able [35]. So far, in OA studies, the role of osteophytes has been widely 
overlooked. However, there is some evidence that during the spatial course of 
knee OA, osteophyte formation may even precede JSN [7], indicating their 
importance especially in the process of early knee OA.  
By scintigraphic studies of elderly subjects with advanced knee OA, it was 
shown that subchondral bone turnover – both formation and degradation – is 
increased [38–39] and accompanied by decreased mineralization [40]. At the 
same time, there is still a remarkable knowledge gap concerning the metabolic 
shifts in subchondral bone in early-stage OA. It is well known that in es-
tablished OA, the thickening of the subchondral plate and an increase in 
trabecular volume results in subchondral sclerosis [34]. On the other hand, 
micro-CT examinations have recently revealed that, in contrast to changes 
found in end-stage OA, at an early stage the subchondral plate thins [34;41–42]. 
These findings suggest that bone remodelling in OA is a biphasic phenomenon: 
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an early decrease in subchondral plate thickness is followed by a phase in which 
the subchondral bone becomes denser and stiffens.  
The above-mentioned understanding of OA pathology indicates that there is 
inadequate data about the metabolic processes taking place in subchondral bone 
during early-stage knee OA. However, there is some radiologic evidence that 
morphological alterations in bone may not develop in a constant manner, as 
perceived before, but seem to have a biphasic course. This calls for further 
evaluation on the biochemical level and on much younger patients with early-
stage OA.  
 
4.1.2.4. The role of inflammation in OA 
Articular cartilage, being avascular, aneural and alymphatic, presents no classic 
features of inflammation. However, at the molecular level, activated chondro-
cytes perpetuate disease progression by the production of a cascade of inflam-
matory mediators [43]. These inflammatory mediators drive catabolic pathways, 
inhibit matrix synthesis, and promote cellular apoptosis [16].  
It is generally accepted that activated synovial tissue contributes to OA 
cartilage pathology [44]. In the osteoarthritic knee, the synovium often develops 
lining cell hyperplasia and hypertrophy and, in some cases, becomes infiltrated 
with subsynovial inflammatory cells [16; 45]. Activated synovial cells secrete 
excess synovial fluid, proteases and cytokines, which accelerate OA progression 
[46]. It is suggested that cartilage breakdown products can also provoke the 
release of collagenases from synovial cells and macrophages and result in 
mononuclear cell infiltration, as well as vascular hyperplasia in the synovial 
membrane.  
This knowledge indicates that to achieve a systematic overview of OA pro-
cesses inflammatory changes in knee joint soft tissues should also be addressed, 
in addition to the alterations in articular cartilage and subchondral bone. 




4.1.3. Clinical criteria of knee OA 
In 1986, the Subcommittee on Osteoarthritis of the American College of 
Rheumatology Diagnostic and Therapeutic Criteria Committee published 
classification criteria for knee OA [47]. These criteria sets were modified into 
algorithms by Altman, facilitating their use in clinical research and population-
based studies [48]. These criteria were based on the presence and duration of 
knee pain, age, morning stiffness, crepitus in active joint motion, radio-
graphically detected osteophytes and laboratory findings of synovial fluid 
changes. Because the major parameter of these criteria is joint pain, these 
criteria help to identify patients with clinically important OA and are therefore 
useful for differentiating patients with OA from those with inflammatory joint 
diseases [49]. The sensitivity of these criteria is rather limited in discriminating 
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patients with early OA from healthy controls [49], because at the individual 
level there is poor correlation between the severity of radiographic changes and 
clinical symptomatology [50]. Thus, in epidemiological studies, radiographic 
criteria remain the basis for classifying subjects as having OA [4; 51]. 
 
 
4.1.4. Imaging methods for diagnosing knee OA 
Up to now, conventional radiography, as an inexpensive and readily available 
imaging modality, has remained the method of choice in assessing the structural 
changes of OA and monitoring disease progression [52–53]. The most 
commonly used OA radiographic grading system was developed by Kellgren 
and Lawrence (KL) in 1957 [54]. This system is based on a global assessment 
combining several features of OA, such as JSN, osteophytes, subchondral 
sclerosis and subchondral cysts, and continues to be widely used even today. 
This system divides OA into five grades (0–4), in which a score ≥2 has 
traditionally been considered to be a definitive radiographic diagnosis of OA 
[49]. However, evidence suggests that KL grade 1 is bona fide OA and distinct 
from KL grade 0, based on the subsequent risk of progression [49]. There has 
been a great deal of criticism of the KL system for its relative insensitivity to 
dynamic changes, poor reproducibility [55] and its global assessment of OA, 
which has advantages only for more severe disease [56–57]. Nowadays, it has 
become clear that increased detail is much more appropriate in the interpretation 
of joint radiographs. In a recent review, it was stated that OA features – JSN 
and osteophytes – involve different pathways and pathophysiologies and are, 
therefore, inappropriately conflated by KL grades. Therefore, ideally these two 
aspects of OA should be looked at individually [6]. It has even been suggested 
that osteophytes alone may be a more reliable indicator of early disease than a 
grade 1 JSN [55; 58]. At the same time, there has been some doubt as to 
whether to treat small osteophytes as a grade 1 OA. In a 10-year follow-up 
study, Hart and Spector demonstrated that 62% of women having small tibio-
femoral (TF) osteophytes at baseline went on to develop true osteophytic knee 
OA, compared with only 22% of controls with no sign of disease [59]. There-
fore, small osteophytes cannot be ignored and should be treated as a subgroup 
of early disease.  
In recent decades, there has been an effort to develop radiographic atlases 
that can be used as guides in the evaluation of individual features of OA [57]. In 
2000, a line drawing atlas was developed by Nagaosa et al that allowed for the 
grading of JSN and osteophyte in TF, as well as in the patellofemoral (PF) 
compartment, and it had several advantages over previous scoring systems [56]. 
This atlas is based on the mathematical calculation of grades from normal JSW 
and the maximum size of osteophytes, giving excellent face validity, separate 
illustrations for grading of JSN for men and women, good reproducibility 
compared with previous atlases, and ease of use.   
Nevertheless, in the majority of knee OA studies conducted so far, the pre-
sence and progression of the disease have still been assessed radiographically 
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on the basis of global KL grade or solely on JSN [38; 60–61], while only a few 
studies have assessed the development of osteophytes as an initial feature of OA 
or its progression [5; 62–63]. 
The natural course of knee OA progression is assumed to be continuous. 
However, a single report by Sharif et al. has suggested that this might not be 
true, as in their study knee OA progression in patients with a mean age of 64 
years turned out to be non-linear over a period of five years [64].  
Although ultrasonography (US) is a less expensive, easily available, well-
established and sensitive diagnostic tool for soft tissue examinations, its role in 
knee OA is widely underestimated, except in patients with acute arthritis. US 
clearly has limitations in terms of assessing articular cartilage pathology; 
nevertheless, it is a reliable method for the demonstration of synovial pathology, 
synovial fluid and bony cortex abnormalities [65].  
There have been only a few systematic investigations dedicated to US 
findings in the case of advanced knee OA [66–68]. DeMiguel Mendieta et al. 
investigated US findings in patients with painful knee OA and found that the 
most frequent US finding was suprapatellar effusion, whereas in patients with-
out pain the most common finding was meniscal lesions [66]. In another knee 
OA study, knee pain was associated with ultrasonographically detected 
effusion, protrusion of the medial meniscus, and displacement of the medial 
collateral ligament [67]. Baker’s cysts have been frequent US findings in 
individuals with painful knee OA [66–68].   
There is currently no data available on the role and benefits afforded by the 
use of this assessment modality in patients with early knee OA. 
Among the new imaging techniques, magnetic resonance imaging (MRI) is 
the most promising and sensitive imaging modality for use in the immediate 
future. MRI is superior in assessing the structure of articular cartilage, sub-
chondral bone and soft tissues, and changes in the disease over time. However, 
its use is limited due to a current lack of accepted and validated scoring 
systems, long examination and interpretation times, and its high cost [5;69–71]. 
So far, ultrasound and MRI have not yet been included in any set of 
diagnostic criteria for OA.  
 
Taking the above facts into consideration, it seems to be necessary to evaluate 
early-stage OA radiographically separately by osteophytes and JSN, and to 
focus on the presence of osteophytes as potentially earlier radiographic signs of 
OA. There is still no data available on the natural progressive course (conti-
nuous or phasic) of early-stage knee OA in middle-aged subjects as well as on 
the benefits of US in assessing soft tissue changes.   
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4.1.5. The prevalence and progression  
of radiographic knee OA in middle-aged subjects 
The vast majority of studies of OA have been conducted on elderly subjects 
with already advanced or even end-stage disease. There is limited data about the 
prevalence of radio-graphic knee OA in subjects younger than 50 years.  
In a Dutch study, radiographic TFOA was found in 7.7%–14.3% of people 
aged 45–49 [72]. Whereas, in a Swedish study, Petersson et al. detected radio-
graphic TFOA (KL grade ≥ 2) in 1.5% of individuals aged 35–54 [73]. The 
same cohort of middle-aged subjects, followed by Thorstensson et al. over 12 
years, revealed that 86% of middle-aged subjects with chronic knee pain 
developed TFOA (KL>or 1) over 12 years and 31%  developed incident PFOA 
over five years [74].  
In the Estonian cohort, the prevalence rate of an advanced (grade ≥2) 
radiographic knee OA, including TFOA and/or PFOA, among 35–55-year-old 
subjects was 3.7% [3]. Among them, the prevalence of advanced TFOA was 
1.7% and of advanced PFOA slightly higher – 2.9% [3]. Schouten et al. 
followed 142 subjects aged 46–68 with radiographic knee OA (KL grade >2) 
over 12 years and observed JSN in 34% of cases [75]. 
Thus, in previous studies, the prevalence and progression of radiographic 
knee OA has been assessed in different ways: based on either TF JSN or KL 
grade level, it is difficult to compare the results of different study groups. There 
is also no conclusive documentation of inter-individual variations in the speed 
and course of knee OA progression. There is a considerable lack of knowledge 
concerning the prevalence and progression of early-stage radiographic knee OA.  
 
 
4.2. Molecular markers of articular tissues in OA 
 
To date, the diagnosis of any disease has usually required the presence of clini-
cal symptoms [49]. However, there is significant evidence that there are often 
early, pre-symptomatic biomarkers of disease, which, if detected, may allow for 
earlier diagnosis and treatment. Therein lies the power and importance of 
applying biomarkers to OA, a disease often characterized by a prolonged 
asymptomatic molecular phase, a pre-radiographic phase, and a later radio-
graphic phase, with visible structural joint changes (Figure 1) [49]. Indeed, 
studies with animal models have shown that subtle biochemical changes in joint 





Figure 1. Different stages in the course of OA 
Figure 1 presents different stages of OA and possible diagnostic means for each stage. It 
is evident that early molecular phase of OA can be assessed only by biomarkers.  
By Virginia Kraus et al.; from Osteoarthritis Cartilage 2011;19:515-42. 
 
 
Biochemical markers of articular tissue metabolism are molecules derived from 
cartilage, bone or soft tissues that are released into synovial fluid, serum and/or 
urine during tissue turnover, at which point they can be assayed by laboratory 
means [78–79]. Biomarkers have the potential to provide an early warning of 
the initiation of articular matrix breakdown, which in future could lead to earlier 
treatment to prevent joint destruction that leads to disability [49]. Thus, mole-
cular markers of joint tissue metabolism have opened novel possibilities for 
earlier diagnosis and monitoring of OA, and are expected to offer means of 
finding subjects with a higher risk for OA progression [49;80–81]. Never-
theless, identification of OA before it becomes evident on radiographs remains 
a challenge. Whether biochemical markers are useful in this process is still un-
clear. So far, the majority of studies on biomarkers have been conducted on 
patients with already advanced radiographically evident structural changes in 
OA. There is a crucial need to evaluate biomarkers much earlier – in the mole-
cular stage of OA, when biochemical changes may be most strikingly evident. 
There is currently a remarkable knowledge gap concerning the benefits afforded 
by the use of biomarkers in early stage OA.  
Metabolic changes in OA involve the interaction of several tissues and 
different pathophysiology pathways and are therefore not adequately repre-
sented by the measurement of a single biomarker. Every single biomarker 
represents a distinct side of metabolism, i.e. the synthesis or break-down of 
bone, or the synthesis or degradation of cartilage. In addition, there are bio-
markers available that reflect the metabolism of articular tissues in general. The 
measurement of a single biomarker is therefore insufficiently sensitive to be 
useful for the diagnosis or monitoring of OA. Nevertheless, in previous studies 
only single biomarkers originating from cartilage or bone tissue have been used, 
which does not offer a full overview of the complex metabolic changes in OA. 
Therefore, the investigation of OA calls for a simultaneous usage of a whole set 
of biomarkers originating from different joint tissues.  
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In recent years, several biomarkers have been studied for their potential use 
in advanced knee OA. Some of the most promising biomarkers, as well as their 
tissue origin, are presented in Table 1. Our study is the first to simultaneously 




Table 1. Molecular markers of articular tissues 
Tissue origin Biomarker Marker characteristics BIPED category  
Cartilage PIIANP Synthesis of type II collagen  BPD 




synovium, bone  
COMP Non-collagenous marker. Mainly cartilage degradation BPD 
Bone, tendon PINP Synthesis of type I collagen  Not categorized 
Bone, tendon CTx-I Degradation of type I collagen B 
Bone OC 
Non-collagenous marker. 
Osteoblast activity, bone 
mineralization 
BPED 
Bone MidOC Non-collagenous marker. Degradation of bone matrix Not categorized  
 
Molecular markers are here presented according to their articular tissue origin and 
characteristic metabolic processes reflected by them.  
Abbreviations: PIIANP – type II A procollagen amino terminal propeptide; CTx-II –  
C-telopeptide fragments of type II collagen; COMP – cartilage oligmeric matrix protein; 
PINP – procollagen type I amino-terminal propeptide; CTx-I – C-terminal cross-linked 
telopeptides of type I collagen; OC – osteocalcin; MidOC – midfragments of osteocalcin. 
BIPED – a classification system developed to categorize biomarkers into five categories 
corresponding to their utility as follows: Burden of Disease, Investigational, Prognostic, 
Efficacy of Intervention, and Diagnostic, for detailes see Text. 
 
 
BIPEDS classification of biomarkers 
Van Spil et al. developed a classification system called BIPED, which cate-
gorizes biomarkers into five categories corresponding to their utility [82]. Re-
cently, the Osteoarthritis Research Society International Federal Drug Admi-
nistration (OARSI FDA) Biomarkers Working Group added a Safety category 
to the BIPED system and, as a result, the acronym for this classification was 
updated to BIPEDS [49].    
The categories of the BIPEDS system are as follows:  
(i) Burden of disease biomarkers indicate the extent or severity of disease and 
can be considered tools for the staging of the disease. 
(ii) Investigative biomarkers are those that show sufficient promise to be 
incorporated into research to determine their utility for subsequent use.  
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(iii)  Prognostic biomarker indicates whether a patient’s disease is likely to 
progress and may also indicate how quickly the progression will occur.  
(iv)  Biomarkers of the efficacy of intervention are expected to demonstrate that 
a drug or intervention has the desired biochemical effect.  
(v)  A diagnostic biomarker indicates whether an individual has the disease or a 
specific subtype of the disease, but may not reflect disease severity.  
(vi)  Safety biomarkers can be used to detect pathological changes and cyto-
toxicity. There are currently no studies that have specifically explored this 
aspect of joint tissue related biomarkers. 
 
 
4.2.1. Molecular markers of cartilage turnover 
Molecular markers reflecting collagen type II synthesis 
Type II collagen is a triple helix composed of three identical alpha-chains. The 
synthesis of type II collagen involves several unique post-translational modifi-
cations. A large precursor molecule, termed procollagen, is processed soon after 
its release from chondrocyte. Type II procollagen is synthesized in two splice 
forms, type IIA and type IIB. Type IIA contains an additional 69-amino-acid 
cysteine-rich domain of the N-propeptide; it is expressed mainly by fetal tissues 
but can be re-expressed by adult chondrocytes of human OA cartilage, sug-
gesting the potential reversion of the cells to a chondroprogenitor cellular 
phenotype in OA [83–84]. Type IIB is expressed at high levels in well-differen-
tiated chondrocytes forming the framework of normal adult cartilage.  
Before the incorporation of type II collagen molecules into fibrils, its non-
helical extensions, termed the amino-terminal type II and carboxy-terminal type 
II procollagen propetides (PIIANP or PIIBNP and PIICP), are cleaved by spe-
cific N- and C-propeptidases. N- and C-terminal propeptides diffuse out of the 
cartilage matrix into the synovial fluid and are cleared into the blood, where 
their concentration can be assayed. The serum levels of these propeptides are 
thus believed to represent the rate of type II collagen synthesis in cartilage 
[81;83]. 
 
Molecular markers reflecting collagen type II degradation 
Type II collagen is degraded by proteolytic enzymes, including the MMPs, the 
cysteine proteases and collagenases [25–26]. MMPs, such as MMP-9 and 
MMP-13, and a series of cystine dependent cathepsins, such as cathepsin K, B, 
L and S, attack collagen at the level of its propeptides [19]. MMP-13 is 
responsible for the generation of the fragment carboxy-terminal telopeptide of 
type II collagen (CTx-II), which is released to joint fluid and subsequently into 
serum and urine, where it can be assayed as a measure of articular cartilage 
breakdown [29]. Immunochemistry studies have indicated that CTx-II is 
abundantly present at the cartilage surface and at the bone-to-cartilage interface 
of the calcified region [19]. Therefore, it has been suggested that the excretion 
of CTx-II may be greater among patients with more advanced knee OA, which 
includes cartilage defects that have full penetration to the bone [85]. 
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Collagenases are able to cleave the native triple helix of collagen, which 
results in the generation of specific neoepitopes at cleavage sites [19]. Among 
them, the neoepitopes C2C and C1,2C have been found to be elevated in OA 
cartilage and body fluids, serving as an another possible laboratory measure of 
cartilage breakdown [86–87]. 
 
Molecular markers of noncollagenous cartilage matrix turnover 
Noncollagenous extracellular matrix proteins in cartilage have roles in modu-
lating the assembly of structural proteins and cross-linking formed networks, as 
well as providing feedback to the chondrocytes on tissue structure and function 
[88]. Among these, the cartilage oligomeric matrix protein (COMP) is a bio-
marker that has been most thoroughly investigated for its potential role for OA 
[83]. COMP is a 524 kDa homopentameric glycoprotein consisting of five 
identical units of 755 amino acid, which belongs to the thrombospondin family. 
[89–90]. Originally considered to be entirely cartilage-specific, COMP has now 
been identified in all articular structures, including ligaments, menisci, tendons, 
synovium, osteoblasts and even vascular smooth muscle cells [91–92]. How-
ever, the concentration of COMP in synovial tissue, ligaments and tendons has 
been shown to be low, even up to 100-fold less than in cartilage and menisci 
[91;93]. Therefore, the major part of circulating COMP most probably origi-
nates from cartilage and has been demonstrated to be representative of cartilage 
catabolism [94]. There is, however, no data available on the exact contribution 
of soft tissue changes to the systemic values of COMP in early stage knee OA. 
 
 
4.2.2. Molecular markers of bone turnover 
Bone turnover is characterized by two opposite activities: the formation of new 
bone by osteoblasts and the resorption of old bone by osteoclasts [83]. Most of 
the collagen in the organic matrix of bone is type I collagen, which is synthe-
sized by osteoblasts and provides a well-organized scaffold for the deposition of 
minerals [95]. Although most of the type I collagen is located in the skeleton, 
this protein is also the most abundant collagen in soft tissues.  
 
Molecular markers reflecting bone synthesis 
The type I collagen molecule is a heterotrimer of two alpha-1 chains and one 
alpha-2 chain, which are wrapped around each other in a triple helix. The two 
additional bulky domains at both ends of the molecule are called the amino-
terminal (PINP) and the carboxy-terminal (PICP) propeptides of type I pro-
collagen: specific by-products that are cleaved from procollagen by two specific 
endoproteinases once the molecule has reached the extracellular space [95]. 
These procollagen propetides are released into the systemic circulation and 
provide an opportunity to assess quantitatively the rate of newly synthesized 
type I collagen [95–96]. In practice, PINP has been shown to have greater 
diagnostic value than PICP as a specific biomarker for bone formation [97–98]. 
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Molecular markers of noncollagenous bone matrix turnover 
Serum osteocalcin (OC), also called bone Gla protein, is a vitamin K dependent 
hydroxyapatite-binding bone specific noncollagenous protein consisting of 49 
amino acids [99–100]. OC is exclusively synthesized by osteoblasts, odonto-
blasts and hypertrophic chondrocytes during the process of bone matrix for-
mation and accounts for approximately 15% of the total noncollagenous protein 
in bone. Although most of the newly synthesized OC is captured by bone 
matrix, a small fraction is released into the blood, where it can be detected by 
immunoassays [83]. In serum, the intact OC molecule is further metabolized by 
the proteases, among them cathepsins, except for the mid-portion of the mole-
cule, which is shown to be resistant to degradation in vitro [101–103]. Circu-
lating OC is therefore constituted of different immunoreactive forms, including 
the intact molecule and various fragments [104–105]. In addition to the newly 
synthesized OC derived from osteoblasts, the circulating OC pool also includes 
fragments derived from the resorption process when OC embedded in the bone 
matrix is released [102; 106–107]. Importantly, OC is known to be involved in 
the inhibition of bone matrix mineralization [108]. Hence, in recent years, OC, 
initially considered to be a marker of bone synthesis, is now believed to be a 
noncollagenous marker of bone turnover and mineralization.  
 
Molecular markers reflecting bone resorption 
The majority of bone resorption markers are degradation products of collagen 
type I, except for tartrate resistant acid phosphatase (TRACP) isoenzyme 5b, 
which mainly reflects the number of osteoclasts, some specific fragments of 
osteocalcin (e.g. the mid-fragment) and bone sialoprotein (BSP) [83]. 
During bone resorption, osteoclasts secrete different factors, such as acid, 
matrix MMPs and cathepsin K. These enzymes degrade type I collagen into 
several products, including the hydroxypyridinium cross-links of collagen, pyri-
dinoline (PYD) and deoxypyridinoline (DPD), the MMP product carboxy-
terminal telopeptide of type I collagen (ICTP) and the combined MMP and 
cathepsin K products type I cross-linked N-and C-telopeptides (NTx-I and CTx-
I) [83]. These cross-linked telopeptides are cleaved specifically from type I 
collagen during bone resorption and are shown to be specific markers of bone 
resorption [83].  
There is emerging evidence that OC detected from serum or urine gives 
qualitatively different information concerning bone turnover [107]. Urinary OC 
represents a heterogeneous pool of different OC fragments that consist mainly 
of the middle portion of the molecule; according to different studies, the pre-
dominant fragment consists of the sequence Asp14-Asp28 [106] and of the 
residues Gly7-Glu31[109]. There is evidence that urinary OC fragments serve as 
an index of bone resorption [107]. It has been shown that the mid-molecule 
fragments of OC were suppressed in post-menopausal women with osteoporosis 
who received bisphosphonate alendronate therapy [106; 110]. It has even been 
suggested that urinary OC fragments may be more specific for bone resorption 
than type I collagen-related markers [83]. In 2005, Kaisa Ivaska et al. (Univer-
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sity of Turku, Finland) developed a novel immunoassay for the detection of 
mid-fragments of urinary OC (MidOC) [107]. There is currently no data avail-




4.3. Molecular markers of joint tissue metabolism  
in incident and/or progressive knee OA 
 
Several biomarkers have been investigated in association with incident radio-
graphic knee OA and disease progression, often with conflicting results. The 
study designs of previous investigations have been variable, with differences in 
the number of investigated subjects, gender profile, age, follow-up time and 
especially the radiographic criteria to define OA and its progression. This may 
explain the discordant results observed with biomarkers across the different OA 
studies [83]. The vast majority of OA studies have been focused only on elderly 
patients (with a mean age ≥ 65 years) with already advanced knee OA (KL 
grade ≥ 2). Therefore, only limited data is available on the early stages of OA 
and the potential value of biochemical markers in early disease.  
 
 
4.3.1. Cartilage markers in incident and/or  
progressive knee OA 
Through cross-sectional studies, several associations have been demonstrated 
between cartilage turnover markers and radiographic knee OA. Garnero et al. 
have shown that the serum values of COMP, as well as urinary output of CTx-
II, were increased in elderly subjects with advanced TFOA (based on JSN) 
compared to age- and sex-matched controls [79]. The same conclusion was 
reached by Jordan et al. and Dam et al. for uCTx-II [111–112]. They 
demonstrated that uCTx-II values were associated with the presence and seve-
rity of knee OA as measured by osteophyte formation, JSN and overall KL 
grade in TF and PF joints [111], or by MRI-detected loss in cartilage volume 
[112]. Serum values of COMP have been shown to be significantly higher in the 
case of TFOA compared to PFOA [113], and associated with the presence of 
clinically diagnosed synovitis [114]. Conflicting data have been published by 
Cibere et al., who found that the risk of radiographic knee OA was higher with 
increasing urinary levels of CTx-II, C2C and C1,C2, but no correlation with 
levels of sCOMP was observed [115]. Also, the serum values of PIIANP, a 
marker for the synthesis of type II collagen, have been shown to be decreased in 
patients with knee OA compared to controls [116].  
In several longitudinal studies using radiographic KL and/or semi-quantita-
tive MRI scores, a predictive value of sCOMP and/or uCTx-II for subsequent 
knee OA progression has been demonstrated [5; 112;114;117–119]. Garnero et 
al. have shown that patients with low levels of cartilage synthesis marker 
sPIIANP and high levels of the cartilage degradation marker uCTx-II had an 
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eight-fold increased risk of OA progression over 12 months, and that the ratio 
of the values of given markers could make the difference between OA progres-
sors and non-progressors [81]. In contrast, in a study by Bruyere et al., no 
correlation was found between the baseline values of sCOMP and subsequent 
one-year MRI-detected change in cartilage volume and thickness in subjects 
with advanced knee OA [120]. On the other hand, a longitudinal study by 
Hunter et al. revealed a prognostic value of serum COMP for subsequent 
cartilage loss on MRI over 2.5 years, but no association with the urinary output 
of CTx-II, C2C or C1,2C was found [121].  
The limited number of previous studies conducted on middle-aged subjects 
has indicated that cartilage markers seem to have both diagnostic [122] and 
predictive [123–124] roles in radiographic knee OA progression at an early 
stage. This finding, however, relies on only three biomarkers: insulin-like 
growth factor-1 (IGF-1) [123], COMP [122] and PIICP [124]. In these studies, 
the follow-up period varied from three to 12 years and assessment of OA pro-
gression was based mainly on TF or PF JSN, except in the study by Schouten et 




4.3.2. Bone markers in incident and/or progressive knee OA 
Much less data is available for the value of bone markers in the case of knee 
OA. In 1995, Sharif et al. demonstrated a correlation between abnormal bone 
scintigraphic scans and synovial fluid levels of bone turnover marker OC in 
patients with knee OA [125]. Nevertheless, there is still limited knowledge 
about the value of bone markers in knee OA and its progression. It is even 
unclear whether OA is characterized by increased or decreased bone turnover. 
So far, the studies available have yielded conflicting data [79]. Except for the 
work by Petersson et al., studies on bone turnover markers have been focused 
on elderly subjects with already advanced-stage knee OA [122]. In the study by 
Bettica et al., it was shown that the urinary levels of bone resorption markers 
CTx-I and NTx-I were higher in patients with progressive knee OA when 
compared to controls [62], indicating the prognostic value of these markers. The 
predictive value of bone markers was also demonstrated by the recent study by 
Berry et al., who found that higher baseline values of the bone formation 
marker PINP and resorption markers CTx-I and NTx-I, as well as the marker of 
bone turnover and mineralization OC, were associated with two-year MRI-
detected reduction in cartilage loss [126]. Moreover, they observed that in the 
subgroup of patients with high sPINP, there was a significant link between 
increased values of CTx-I and NTx-I and a reduced rate of cartilage loss. At the 
same time, Bruyere et al. found no predictive association between the baseline 
values of OC or CTx-I and a 12-month loss in cartilage thickness and volume 
using MRI [120]. Interestingly, cross-sectional studies on advanced knee OA 
have even indicated a decrease in the values of sCTx-I, uCTx-I and OC [79], or 
no significant change at all [111;115].  
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In the only bone marker study available for middle-aged subjects, with a 
mean age of 47 years, increased serum levels of BSP were found in individuals 
who developed radiographic TF and PF knee OA over the following three years 
[122].  
Except for the study by Berry et al. [126], previous investigations of bone 
markers have focused mainly on the resorption of bone. The other part of bone 
turnover – the synthesis of type I collagen (reflected in the levels of PINP) – has 
been overlooked. Instead of PINP, serum levels of a noncollagenous marker OC 
were assayed as a measure of bone formation [79;111;120]. However, OC as a 
general marker of bone turnover reflects the formation and resorption of bone 
matrix in combination [107], and might be more useful as a marker reflecting 
the inhibition of bone matrix mineralization [108].  
There is still a significant lack of knowledge regarding the diagnostic and 
prognostic utility of bone markers in early OA, and no data are available on the 
possible value of the specific bone formation marker PINP in patients with early 
knee OA.  
 
Even less data is available on potential associations between biomarkers and 
ultrasonographically detectable changes in knee joint soft tissues during OA 
[127]. A single study by Jung et al. established that the serum levels of hylau-
ronic acid (HA) and COMP increased in elderly patients with longer medial 
osteophytes and capsular distension of the knee joint and, in the case of HA, 
also with effusion and/or synovial proliferation. 
There are, however, no data available on the possible associations between 
biomarkers and US-detected soft tissue changes of the knee joints in middle-
aged subjects with early-stage OA.  
 
The conflicting data from the above studies indicate that the complexity of the 
OA process calls for more extensive studies and a more systematic approach. 
Therefore, a panel of biomarkers reflecting the formation and degradation of 
both collagenous and noncollagenous parts of both cartilage and bone would 
allow for a more systematic look at complicated metabolic processes. There are 
still minimal data available on articular turnover markers in middle-aged 
subjects with early-stage knee OA – a stage when biochemical alterations of 




5. AIMS OF THE STUDY 
 
To enhance the knowledge of the long-term radiographic and biochemical be-
haviour of knee OA in middle-aged subjects at an early stage of the disease.  
 
Specific aims: 
 To specify what kind of lesions or processes in the OA-affected knee joint 
are reflected by the values of serum COMP and the novel bone marker 
urinary MidOC. 
 To determine the prevalence and progression of radiographic features of OA 
in middle-aged subjects with chronic knee joint complaints. 
 To clarify the potential relationships between molecular markers of cartilage 
and bone metabolism and ultrasonographically detected changes in knee 
joint soft tissues in subjects with early-stage knee OA. 
 To examine the potential diagnostic and prognostic value of cartilage bio-
markers in progressive cases of knee OA. 
 To examine the potential diagnostic and prognostic value of bone bio-




























6. MATERIALS AND METHODS 
 
6.1. Study subjects 
 
Subjects with persistent (> three-month duration) knee complaints were identi-
fied using a questionnaire sent to a random sample of individuals aged 35–55 
from the register of a general practitioner in the southern Estonian town of Elva 
[3]. An initial invitation was sent to 559 randomly selected subjects to parti-
cipate in the study. Of those invited, 348 (62%) responded. Out of the 348 
responders, 220 admitted either knee pain (60%) or other knee symptoms 
(40%), such as crepitation and stiffness. Out of 220 subjects, 161 (73% of those 
with knee complaints; 101 women and 60 men) agreed to participate in the 
longitudinal study and were examined at three different time points, at baseline 
(in 2002), after three years (in 2005) and after six years (in 2008). Over the six 
years, 33 subjects out of the 161 (20%) were lost to follow-up. The reasons for 
participants being not eligible or available for follow-up included refusal 
(n=21), leaving the study area (n=9), death (n=1), and inability to contact (n=2). 
Knee joint radiographs were available for at least two time points, the 
baseline and at the end of the study, for 128 subjects out of the 161, and these 
subjects were included in the present study. The patient characteristics are 
presented in Table 2. The distribution of age, gender and BMI of these 128 
subjects did not differ significantly from the initial group of 220 individuals.  
 
 
Table 2. Characteristics of the study participants 
Characteristics 







Baseline age, mean +/- SD years 45.0 +/- 6.2 46.9 +/- 5.4 0.116 
Baseline BMI, mean +/- SD kg/m3 27.6 +/- 5.1 27.7 +/- 5.4 0.928 
Women  85/128 (66%) 16/33 (48%) 0.417 
Baseline radiographic knee OA † 73/128 (57%) 21/33 (64%) 0.752 
Baseline radiographic knee OA grade 2-3 ‡ 7/128 (5.5%) 1/33 (3%) 0.100 
 
Except where indicated otherwise values denote the number/total number (%) of 
patients.  
* By the chi-square test for categorical variables and by the Mann-Whitney U-test for 
continuous variables 
BMI – body mass index 
† Knee OA grades 1, 2 and 3 according to the grading system of Nagaosa. 
‡ Knee OA grades 2 and 3 according to the grading system of Nagaosa. 
 
 
Out of the 348 responders, 108 reported no knee joint complaints, and among 
them 73 agreed to participate in the longitudinal study. Out of the 73 subjects, 
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40 (15 males and 25 females) had no radiographic signs of knee OA and served 
as controls.  
There were no statistically significant differences in mean age or BMI 
between the female and the male subjects. The proportion of post-menopausal 
women was 35% at baseline and 45% at the end of the study. Subjects with 
radiographic evidence of rheumatoid arthritis or other inflammatory arthro-
pathies in the knees were not included in the study.  
To investigate the potential value of a novel bone biomarker, MidOC, 19 
post-menopausal women with osteoporosis, aged 49–66 (mean 60), receiving 
bisphosphonate treatment with risedronate 35 mg weekly for 12 months were 
followed. Osteoporosis was diagnosed if the T score of lumbar spine bone 
mineral density (BMD) (L2-L4) was less than –2.5 by dual-energy X-ray 
absorptiometry, DXA (DPX-IQ, Lunar Corp). These patients were examined for 
BMD at baseline and after 12 months. Women were considered responders to 
the therapy if the 12-month change in BMD exceeded +3% from the baseline 
value. The levels of bone markers, among them MidOC, were investigated in 
relation to the changes in BMD at five different time points (0, 1, 3, 6 and 12 
months) during therapy. 
Written informed consent for participation was obtained from each subject 
according to the Declaration of Helsinki. The study protocol was approved by 
the Ethics Committee for Human Research of the University of Tartu.  
The study subject allocation, according to different papers, is presented in 
Figure 2.  
 
 
Figure 2. Study subjects 
Study subjects allocation according to different papers. 
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6.2. Standardized radiographic investigation 
 
The TF and PF joints of both knees were radiographed separately. Standardized 
radiographs of the TF joints were taken with the subject in a standing frontal 
antero-posterior position, with the knee joints in full extension and with equal 
weight on both legs. Axial views of the PF joints were taken with the subject in 
a standing position, with knee joints at 60° of flexion according to the technique 
described by Boegard et al. [128]. JSN and osteophyte (Oph) size were classi-
fied on four-point scales (grades 0–3) according to the system of Nagaosa et al. 
[56]. JSW were measured separately for the medial and lateral compartments. 
Osteophyte size was determined in eight distinct regions of interest (ROIs) in 
each knee joint: medial and lateral femoral condyle, medial and lateral tibial 
plateau, medial and lateral patella, and medial and lateral trochlea. The presence 
of subchondral sclerosis was not considered for OA grading. TFOA and PFOA 
grades were defined as the highest grade documented in any ROI. The global 
grade of knee OA for each subject was based on the status of TF and PF joints 
for both knees. The radiographic OA grade 1 was diagnosed if at least a single 
osteophyte (grade 1) and/or JSN (grade 1) was assessed in any ROI. OA grade 2 
was diagnosed if an osteophyte with grade 2 and/or JSN (grade 2) was assessed 
in any ROI. OA grade 3 was considered to be present if an osteophyte with 
grade 3 and/or JSN (grade 3) was assessed in any ROI.   
 
The criteria for radiographic OA grade progression were defined as:  
(i) the presence of osteophytes and/or JSN in subjects with no previous 
radiographic evidence of OA or  
(ii) an increase in the grade and/or number of already existing osteophytes 
and/or JSN grade over three and/or six follow-up years. 
In addition, a subset of patients was identified whose OA grade did not change 
over the follow-up period, but who developed JSN or osteophytes in new lo-
cations: “minimal progressors”.  
 
All radiographs were interpreted by an experienced radiologist who was blind to 
clinical details. To assess radiographic progression, radiographs from different 
time points were examined in pairs to ensure consistent evaluation over time.  
 
 
6.3. Ultrasonographic examination 
 
US of both knees of all subjects was performed by a single experienced 
musculoskeletal radiologist blind to the results of clinical, radiographic and 
laboratory examinations, using a multi-frequency linear 7.5 MHz probe. The 
presence of osteophytes, thickness of tendons, cartilaginous structure, meniscal 
changes, synovial hyperperfusion, effusion, and the presence of Baker’s cysts 
was assessed according to EULAR guidelines [129] and graded on a 0/1 scale. 
In addition, calcification in the quadriceps and patellar tendons and defects in 
the subchondral bone contour were documented.  
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US data were available for 106 individuals (33 men and 73 women), who 
constituted a subset of an initial population-based cohort of 240 subjects with 
persistent (> three months) pain in one or both knees. The mean subject age was 
49 years (range, 36–55 years). 
 
 
6.4. Laboratory investigation 
 
Serum samples were obtained at all three time-points, at baseline, after three 
and six years, and second-morning urinary void samples were collected at the 
three- and six-year follow-ups. All samples were stored frozen at –70°C until 
measured.   
Specific synthesis and degradation markers were implemented separately for 
bone and cartilage. In addition, two markers – OC and COMP were used to 
reflect the metabolism of bone and articular tissue in general.  
Cartilage formation was estimated by measuring serum concentrations of 
type II A procollagen amino-terminal propeptide (sPIIANP). Serum PIIANP 
was measured by enzyme-linked immunosorbent assay (ELISA), using a poly-
clonal antibody raised against recombinant GST-human type II procollagen 
exon 2 fusion protein (Synarc, Lyon, France). The assay was based on the com-
petition between circulating PIIANP and recombinant fusion protein GST-exon 
2 for the binding to the polyclonal antibody immobilized on a micro-titreplate. 
Standards and serum samples were incubated for 4 h with shaking at room 
temperature with 100 µl/well of IIA antiserum. After washing, the peroxidase 
conugated anti-rabbit (diluted: 1/8000, Sigma, St Louis, MO) was added (100 µl/ 
well) and incubated at room temperature for 1 h with shaking. After washing, 
100 µl H2O2/Tetramethylbenzidine substrate-indicator solution (Sigma, St 
Louis, MO) was added. After incubation at room temperature for 30 min with 
shaking, the colour reaction was stopped by the addition of 100 µl 2M 
H2SO4/well and the optical density was read at 450 nm in a Dynatech MR 7000. 
Each sample was run in duplicate. 
Cartilage degradation was estimated by assaying the urinary concentrations 
of the C-telopeptide fragments of type II collagen (uCTx-II). The concentrations 
of CTx-II were determined in a competitive ELISA, using a monoclonal 
antibody mAbF46 raised against a linear six-amino-acid epitope of the type II 
collagen C telopeptide (Urine CartiLaps®, Immunodiagnostic Systems, Herlev, 
Denmark). A biotinylated CTX-II C-telopeptide derived peptide (EKGPDP) 
was coated on a streptavidine microtitre plate, and sample and the primary anti-
body (mAbF46) were added. After overnight incubation, the amount of bound 
antibody was quantified using a peroxidase-labelled secondary antibody and a 
chromogenic peroxidase substrate. The concentration of the CartiLaps ELISA 
(ng/l) was normalized against urinary creatinine concentrations (mmol/l), which 
were measured by Jaffe's kinetic method (as ng/mmolCrea). For this, the 
following formula was used: corrected CTX-II value (ng/mmol) = 1000 x urine 
CartiLaps (μg/L) / creatinine (mmol/L). 
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A serum concentration of the general joint tissue marker sCOMP was 
assayed by a solid-phase, two-site enzyme immunoassay based on the direct 
sandwich technique, in which two monoclonal antibodies are directed against 
separate antigenic determinants on the COMP molecule [COMP® ELISA,  
AnaMar Medical, Göteborg, Sweden]. During incubation, COMP in the 
samples reacted with peroxidase-conjugated anti-COMP antibodies and anti-
COMP antibodies bound to the microtitration well. Using a single washing step, 
unbound enzyme-labeled antibody was removed. The bound conjugate was then 
detected by a reaction with 3,3`5,5`-tetramethylbenzidine (TMB). This reaction 
was stopped by adding acid to give a colorimetric endpoint that was read 
spectophotometrically.  
Bone formation was assessed by serum concentration of procollagen type I 
amino-terminal propeptide (sPINP). Bone resorption was estimated by the se-
rum level of the C-terminal cross-linked telopeptides of type I collagen (sCTx-I) 
and by the urinary level of MidOC. The serum concentrations of PINP and 
CTx-I, and of the general marker of bone turnover and its mineralization – 
serum OC – were assayed by an automated electrochemiluminescence immuno-
assay (ECLIA, Elecsys), according to the directions for use by Roche.  
Urinary MidOC were assayed by ELISA implementing two monoclonal 
antibodies: Mab6F9, which binds to the residues Gly7-Arg19, and Mab3H8, 
which recognizes the fragment Arg20-Arg43. The values of uMidOC were nor-
malized for urinary creatinine, which was measured by Jaffe`s kinetic method.  
The intra-assay variations for PINP, CTx-I, OC, MidOC, COMP, CTx-II and 
PIIANP were 3%, <4%, <4%, <3%, <10%, 4% and <9%, respectively, and the 




6.5. Statistical analysis 
 
Descriptive statistics were calculated for sex, age and presence of radiographic 
knee OA grades and compared between subjects who had returned and those 
who were lost to follow-up by a chi-square test for categorical variables and by 
the Mann-Whitney U-test for continuous variables.  
As biomarkers did not follow normal distribution, non-parametric methods 
were used for statistical evaluation. 
The associations between the biomarker values and radiographic progression 
of the knee OA features (osteophytes and JSN) were assessed by Spearman’s 
rank correlations.  
The diagnostic and prognostic value of each biomarker for radiographic knee 
OA progression was assessed by the Mann-Whitney U-test, comparing the 
values of the biomarkers for the OA progressors and the non-progressors. 
The risk of radiographic knee OA progression with increasing bone marker 
values was calculated by logistic regression analysis (odds ratios), with adjust-
ment for age, gender and BMI. 
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Multiple linear regression analysis was employed to assess the ability of US 
parameters to predict the variability of biomarker values. Several models of US 
parameters were tested to find the best set of US parameters for each given 
marker. 
A p value <0.05 was considered statistically significant. For statistical com-


























7.1. Serum COMP and urinary MidOC – specifications  
for their usage as molecular markers of joint tissue 
metabolism (Papers I–II) 
 
7.1.1. Serum COMP – a marker reflecting metabolic changes  
in several articular tissues  
Serum COMP was initially considered an entirely cartilage-specific macromole-
cule reflecting cartilage degradation. Later evidence was gathered that in OA 
patients serum COMP might also be released from such joint soft tissues as 
tendons, ligaments, menisci and synovium.  
Using cross-sectional analysis, we investigated what kind of knee joint 
structures might be associated with increased levels of sCOMP in subjects with 
early knee OA. Our findings, based on the correlations between serum COMP 
values and radiographic and ultrasonographic changes, revealed that in early-
stage knee OA there is an important contribution of TF osteophytosis, as well as 
soft tissue changes in the values of COMP (Table 3). Among the latter, 
meniscal changes made the largest contribution to the systemic level of COMP. 
Based on the above findings, we could confirm the view that COMP is a general 
marker of joint tissues. Compared to the entirely cartilage-specific biomarkers, 
COMP might reflect even better the changes in the OA joint, as it consists of 
the contributions of different articular tissues (Paper I). 
 
Table 3. Comparison of serum levels of COMP between the groups with and without 
radiographic and ultrasonographic findings 
 
              Variable  
                   The median values of S-COMP 














TF osteophytes (by X-ray)                
n= 26/12* 10.7 9.5 0.029 12.4 12.0 0.904 
PF osteophytes (by X-ray)              
n= 16/28* 9.8 9.8 0.343 11.9 12.2 0.443 
Tibial osteophytes (by US)              
n=5/4* 12.8 9.7 0.005 13.0 11.7 0.268 
Femoral osteophytes (by US)            
n=6/3* 12.4 9.7 0.019 12.3 11.7 0.564 
Meniscal changes (left, by US)         
n= 5/3* 12.8 9.7 0.043 14.6 11.6 0.022 
Meniscal changes (right, by US)       
n= 8/6* 10.1 9.8 0.446 11.2 11.8 0.369 
Differences between groups by Mann-Whitney U-test. 
US – ultrasonography 
*    – the number of females/males with lesions 
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7.1.2. Urinary MidOC – a novel marker of bone resorption 
Serum OC is derived from osteoblasts and is therefore widely used as an index 
of bone formation. The intact OC molecule accounts for approximately one-
third of total OC, while the rest is composed of fragments. The presence of 
multiple immunoreactive OC fragments was demonstrated in the urine as early 
as 1990 [102]. There was evidence that some urinary fragments of OC might 
reflect bone matrix resorption, not formation. So far, urinary OC mid-fragments 
have not been tested in OA patients. 
To evaluate the possible resorptive origin of urinary OC mid-fragments, we as-
sayed these fragments along with other markers of bone resorption (sCTx-I), 
synthesis (sPINP) and mineralization (sOC) in a 12-month follow-up study on 19 
post-menopausal women receiving bisphosphonate – risedronate treatment (Paper 
II).  
A parallel significant decrease was observed in the levels of uMidOC and 
the well-characterized bone resorption marker sCTx-I after the first month of 
risedronate treatment, while the levels of sOC and sPINP did not differ from the 
pre-treatment values at this time point (Figure 3). In the course of the first six 
months of therapy, the correlation between uMidOC and sCTx-I (r(s)=0.511, 
p=0.0003, n=45) was more pronounced than the correlation between uMidOC 
and sPINP (r(s)=0.312, p=0.039, n=44). These results provide further evidence 
that urinary OC mid-fragments and serum total OC reflect different aspects of 
bone turnover. The quick response of uMidOC to antiresorptive therapy indi-
cates its mainly resorptive origin (Paper II). Based on these follow-up data, we 
succeeded in validating uMidOC as a new marker of bone matrix resorption, 
with the aim of its further evaluation in knee OA patients. 
 
Figure 3. Longitudinal changes in bone turnover markers in response to 12 months 
risedronate therapy.  
The results are presented as T-scores for each marker compared to the control group.  
T-scores were calculated as: (observed result – mean of controls) / SD of premenopausal 
controls. Changes greater than one T-score (1 SD) were considered as response to therapy. 
The response of uMidOC to risedronate compared to the pre-treatment T-score value is 
marked by:  * p< 0.05,  ** p<0.002. 
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7.2. Results of radiographic investigations 
 
To determine the prevalence and progression of early-stage radiographic knee 
OA, we prospectively evaluated a population-based cohort of middle-aged sub-
jects over six consecutive years.  
 
 
7.2.1. The prevalence of radiographic knee OA (Paper III) 
At baseline, less than half of the studied subjects (44%) had no radiographic 
sign of OA (grade 0), and the rest had mild OA in different combinations. The 
details are presented in Table 4. Only seven subjects out of 128 (5%) presented 
with OA grade 2 or 3. It is important to note that as many as 20% of the subjects 
with OA grade 1 had isolated PF involvement.  
 
 
Table 4. The prevalence of radiographic knee osteoarthritis at baseline and 6- year 
follow-up 
OA grade At baseline At 6-yr follow-up 
OA grade 0 56 (44%) 23 (18%) 
OA grade 1 65 (51%) 86 (67%) 
TFOA=1 20 24 
PFOA=1 25 16 
TFOA + PFOA=1 20 46 
OA grade 2 6 (4%) 16 (13%) 
TFOA=2 3 7 
PFOA=2 1 6 
TFOA + PFOA=2 2 3 
OA grade 3 1 (<1%) 3 (2%) 
TOTAL 128 128 
 




When the features of OA were analysed separately, we found that in 57% of the 
subjects with OA the diagnosis was based on osteophytes alone, in 13% on 
isolated JSN, and in 30% on both. 
After six years, we observed a remarkable decrease in the number of subjects 
with no radio-graphic knee OA (grade 0). Of the subjects with OA grade 1, 
approximately 60% had both TFOA and PFOA in combination, twice the 
percentage as at baseline (Figure 4). Relative to baseline, 12 new subjects were 
diagnosed with OA grade 2–3. The distribution of knee OA grade did not differ 
significantly between males and females. 
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Figure 4. Distribution of radiographic knee OA grades at baseline and after 6 years. 
Here are presented the radiographic data of 128 subjects at baseline and after 6 years. At 
baseline, the majority of subjects with radiographic knee OA had only grade 1 (65 out 
of 72). Note that 25 of them had isolated PFOA grade 1.  In 56 subjects no radiographic 
OA was present at baseline. At 6-yrs follow-up we observed 86 subjects with OA grade 
1 and 19 with grade 2–3. Relative to baseline, 12 additional subjects were diagnosed 
with OA grade 2–3. 
 
 
7.2.2. Radiographic knee OA progression 
over six years (Paper III) 
Over six years, we observed radiographic OA grade progression in 71 subjects 
out of 128 (56%); of these, 35 had progression only in TFOA, 22 only in PFOA 
and 14 in both (Figure 4). Thus, we observed radiographic OA progression in 
more than half of the studied middle-aged subjects. However, in the majority of 
progressive cases it was an early stage OA: progression from OA grade 0 to 
grade 1. Moreover, the progression was largely based on the development of 
osteophytes alone (31/71), or osteophytes in combination with JSN (26/71). At 
the same time, progression based on JSN alone accounted for only 20% of the 




7.2.2.1. Radiographic knee OA progression  
in two consecutive three-year follow-up periods  
During the first three years of follow-up, 49 of 119 subjects (41%) showed OA 
grade progression, including 30 with progression only in TFOA, 15 only in 
PFOA and four in both. 
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During the second three-year period, only 28 of 119 subjects (24%) showed 
radiographic OA progression, including 10 with TFOA progression, 15 with 
PFOA progression, and three with both. 
The number of TFOA progressors was significantly higher over the first 
three years of follow-up when compared to the last three years (Chi square 12.0, 
p=0.0005), whereas the number of PFOA progressors was the same over both 
periods. In the majority of cases, TFOA progression did not proceed during the 
second period of observation. Thus, the radiographic course of OA over six 
years followed a non-continuous pattern with periods of progression and 
stabilization. 
 
7.2.2.2. Individual pattern and types  
of knee OA progression over six years   
A more detailed analysis, based on the individual course of OA progression 
over six years, revealed five distinct groups of OA progression (Table 5). Of 
the total of 120 subjects, 40% showed no knee OA progression (subdivided as 
“stable OA” and “no OA” groups). Most of the remainder (41/120) were 
classified as “first phase progressors” – progression only in the first three years 
of follow-up; 21 as “second phase progressors” – progression only in the last 
three years of follow-up; and seven as “continuous progressors” – progression 
during both periods.  
 
 
Table 5. Patterns of radiographic OA progression over 6 years  
Radiographic progression 
group n 
First 3 years of 
follow-up 
Last 3 years of 
follow-up 
First phase progression * 41 progression no progression 
Second phase progression † 13 no progression progression 
Continuous progression ‡  7 progression progression 
Stable OA § 28 no progression no progression 
No OA  20 no OA  no OA 
 
*  Including 26 subjects with TFOA progression, 11 with PFOA progression and 4 with 
both. 
† Including 4 subjects with TFOA progression, 7 with PFOA progression and 2 with 
both. Of the initial group of 21 subjects with late progression, 8 were excluded because 
they were of significantly younger age and did not have OA at baseline.  
‡ Including 4 subjects with TFOA progression and 3 with PFOA progression over the 
first 3 years of follow-up, and 3 with TFOA progression and 4 with PFOA progression 
from the last 3 years of follow-up.  
§ Including 8 subjects with TFOA grade 1, 5 with PFOA grade 1, 13 with TFOA+PFOA  
grade 1, 1 with TFOA grade 1 + PFOA grade 2 and 1 with TFOA grade 2 + PFOA grade 1.  
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The results of this detailed analysis revealed again that the overall OA pro-
gression is non-continuous and heterogeneous, as in half of the cases there were 
periods of progression and stabilization. In three-fourths of the cases, the OA 
process either did not progress or progressed with intermittent stops. Therefore, 
the overall OA progression proved to be slow. However, at the same time, there 
were a few cases with continuous progression of OA. 
 
 
7.3. Effect of age, gender, BMI and menopausal status on 
serum and urinary values of biomarkers 
 
In every studied subject, specific synthesis and degradation markers of bone 
(sPINP, sCTx-I and uMidOC) and cartilage (sPIIANP and uCTx-II) were 
assayed. In addition, sOC was used to assess changes in bone mineralization 
and sCOMP – to reflect the metabolism of articular tissues, among them soft 
tissues in general. 
We did not find any statistically significant differences in the median values of 
biomarkers between male and female control subjects. However, in subjects with 
chronic knee complaints, we observed significantly higher median values of four 
biomarkers (COMP, PIIANP, CTx-I, and MidOC) in males when compared to 
females. The median values for males and females are presented in Table 6.  
 
 
Table 6. Median concentrations of biomarkers in subjects with chronic knee complaints 
 
Biomarker Males Females Unit p value Median +/- SD Median +/- SD 
sCOMP 11.8 (3.2) 9.7 (2.6) U/L 0.001 
uCTx-II 121.2 (121.3) 172.4 (128.3) ng/mmol Crea ns. 
sPIIANP 766.2 (370.1) 670.2 (212.0) ng/mL 0.016 
sPINP 43.1 (14.3) 41.4 (18.1) µg/L ns. 
sCTx-I 0.43 (0.2) 0.38 (0.2) µg/L 0.039 
sOC 22.7 (7.1) 22.2 (10.1) µg/L ns. 
uMidOC 1.45 (0.7) 1.01 (0.9) µg/mmol Crea 0.025 
 
By Mann-Whitney U-test. 
SD – standard deviation. 
 
 
Only in the case of PIIANP were the median values significantly higher in 
subjects with chronic knee pain when compared with controls. The respective 
median values for males and male controls were 766.2 and 437.2 ng/ml and for 
females and female controls 670.2 and 357.6 ng/ml (p<0.0001 for both males 
and females).  
As expected the levels of biomarkers were significantly dependent on the 
ages, BMI and menopausal status of the subjects.  
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In female patients, COMP, CTx-II, PINP and OC values were closely 
associated with age, CTx-II and PIIANP were significantly associated with BMI 
and all studied biomarkers except PIIANP were affected by menopausal status. 
In males the input of BMI seemed to be the most important confounder for the 
systemic values of biomarkers – all studied bone markers (PINP, CTx-I, OC, 
MidOC) were closely associated with BMI.  
Therefore, all the following results presented in the present study are ad-
justed for gender, age, menopausal status and BMI. 
 
 
7.4. Associations between joint tissue biomarkers and 
radiographic knee OA at three different time-points 
(Paper V)  
 
In our study, OA was radiographically assessed in two different ways: by global 
OA grades and separately by OA features: osteophytes and JSN. There was no 
significant correlation between the values of bone markers and global knee OA 
grades (TFOA and PFOA) at any studied time point. However, several statisti-
cally significant associations were observed between biomarkers and JSN and/ 
or osteophytes if they were analyzed separately (Tables 7 and 8 for cartilage 
and bone markers, respectively). 
 
 
Table 7. Correlations between cartilage markers and radiographic features of OA at 


















oph PF oph 
COMP F * F *   M *     M *    F *** 
M **   
F * NA 
CTx-II NA NA F ***       F ***   M * 
PIIANP NA NA     M *INV 
M  
*INV   F * NA 
 
Cross-sectional associations between the values of cartilage markers and features of 
knee OA examined at three different time points.  
By Spearman’s rank correlations. 
Presented data are adjusted for age, BMI and menopausal status. 
Abbreviations: 
M – males, F – females, INV – inverse correlation, NA – biomarker not assayed at 
given time point, Oph – osteophytes, JSN – joint space narrowing 




Table 8. Correlations between bone markers and radiographic features of OA at three 




Baseline 3-year follow-up 6-year follow-up 
Medial 





PF JSN TF oph PF oph 
PINP     
M * 
inv     F * 
CTx-I  F * F *         
OC       F * * M * inv   
MidOC   F * *         
 
Cross-sectional associations between the values of bone markers and features of knee 
OA examined at three different time points.  
By Spearman`s rank correlations. 
Presented data are adjusted for age, body mass index, and menopausal status. 
Abbreviations: M – males, F– females, INV – inverse correlation, Oph – osteophytes, 
JSN – joint space narrowing,  
* p < 0.05, ** p < 0.01 
 
 
It is remarkable that the observed associations between biomarkers and radio-
graphic OA features were different over the course of six years. For example, in 
females, at baseline and at the three-year follow-up, bone resorption (by CTx-I) 
was associated with medial TF JSN, whereas at the six-year follow-up the 
correlation turned out to be non-significant. At the six-year follow-up, a signi-
ficant association (not observed before) was evident between OC and PF JSN. 
At the same time, at the three-year follow-up, cartilage degradation (by CTx-II) 
was strongly associated with TF osteophytes, a correlation that was not seen 
later at the six-year follow-up, whereas at the three-year follow-up cartilage 
synthesis (by PIIANP) was inversely associated with TF and PF JSN only in 
males.  
The above results indicated that over the course of six years the associations 
between biomarkers and radiographic knee OA were largely dependent on (i) 
gender, (ii) time point and (iii) OA feature. 
 
 
7.5. Associations between biomarkers and 
ultrasonographic features in OA (Paper IV) 
 
In middle-aged subjects with knee complaints, nine different parameters were 
ultrasonographically differentiated (Table 9). Among them, the most prevalent 
findings were calcification in the patellar and quadriceps tendons, synovial 
thickening, suprapatellar effusion, Baker’s cysts, changes in the structure of the 
femoral cartilage, and meniscal changes. Several US parameters were in-
fluenced by age and BMI (Table 9). The associations between US findings and 
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BMI were found to be gender-specific, with most applying only to women. 
Such US features as tendon calcification, meniscal changes and femoral osteo-
phytes were associated with age. 
 
 
Table 9. Ultrasonographic findings in early stage knee OA and associations between 
US features, age, and BMI 
 
Ultrasonographic features n Age BMI 
Calcification in tendons # 65 0.42 *** 0.21 * 
Thickening of synovia 33 
 
– 0.05 0.21 * 
Suprapatellar effusion 27 0.10 – 0.24 * 
Baker’s cysts 24 0.12 0.07 
Changes in cartilage structure 20 0.11 0.08 
Meniscal changes 14 0.21 * 0.23 * 
Defects in subchondral bone 12 0.21 * 0.20 * 
Femoral osteophytes 10 0.26 ** 0.23 * 
Synovial hyperperfusion 6 – 0.06 – 0.23 * 
 
 
* p<0.05, **p<0.01, *** p<0.001 by Spearman’s rank correlation.  
# – here are presented the summary cases of tendon calcifications in all locations. 
Calcifications in quadriceps tendons and patellar tendons were documented separately 
in 50 and 40 cases, respectively.  
 
 
Surprisingly, all of the studied bone markers were associated with at least some 
US findings. In pre-menopausal women, thickness of the synovium and the 
presence of Baker’s cysts predicted up to 20% of the overall variability of bone 
collagen synthesis (by PINP; Table 10). The serum values of OC were sub-
stantially influenced by the presence of suprapatellar effusion. In men, a strong 
association was observed between tendinal calcifications and bone collagen 
synthesis (by PINP; Table 11).  
The presence of tendinal calcifications was accompanied by the degradation 
of cartilage collagen (by CTx-II). In addition to routinely ultrasonographically 
followed suprapatellar effusion, meniscal changes and the presence of Baker`s 
cysts turned out to play substantial roles in the prediction of cartilage marker 
values.  
The associations between soft tissue changes and cartilage markers were 
most strongly expressed in post-menopausal women (description of COMP up 
to 29 %, and CTx-II up to 35%, Table 10). In males, both sides of cartilage 
metabolism (synthesis and resorption) were enhanced in the presence of soft 






























































































































































































































































































































































































































































































































































































































































































































Table 11. Correlations between ultrasonographic findings and biomarkers of bone and 



















 PINP *        13.7 
U-CTx-II    ***  * * 24.5 
PIIANP * **   *     38.1 
 
*  p<0.05, ** p<0.01, ***  p<0.001 by Spearman’s rank correlation.  
US parameters that showed significant correlation with the levels of a given marker 
were included in the regression model to describe the contribution of such findings to 
the total variability of the marker, using multiple linear regression analysis.  
Abbreviations: Calcif. pat. tend – calcification in the patellar tendon, Calcif. quad.  
tend – calcification in the quadriceps tendon, Cart. struct.def. – defect in cartilaginous 
structure, Oph – femoral osteophytes, TC – thickening of synovia, Thick. cart. – 
thickness of the femoral cartilage.  
 
 
US-detected soft tissue changes were common in early-stage knee OA. The 
variability of bone and cartilage biomarkers was substantially dependent on the 
accompanying status of soft tissues. The above associations were substantially 
influenced by the patient’s gender.  
 
 
7.6. Associations between cartilage and bone biomarkers 
and radiographic knee OA progression (Papers V–VI) 
 
7.6.1. The diagnostic and prognostic value of cartilage markers in 
radiographic knee OA progression (Paper V)  
7.6.1.1. Cartilage markers over the six-year follow-up if knee OA progression 
was expressed by global OA grades  
In general, there was no statistically significant difference in the values of the 
cartilage markers (sCOMP, PIIANP and uCTx-II) between the progressors and 
non-progressors when we focused only on the changes in global OA grades 
(TFOA, PFOA). However, an exception was noted for uCTx-II, whose three-year 
follow-up concentrations (in 2005) were significantly higher in males who 
developed PFOA progression over the first three years of follow-up (2002–2005) 
when compared to subjects without radiographic knee OA; the median 
concentrations for the progressors and “no OA group” were 342 and  
220 ng/mmolCrea, respectively, p=0.007. The three-year follow-up concentrations 
of uCTx-II (in 2005) were also higher in subjects who developed a combined 
progression in TFOA+PFOA over six years when compared to the individuals 
without radiographic evidence of knee OA; the medians for progressors and “no 
OA group” were 247.6 and 188.1 ng/mmolCrea, respectively, p=0.045. 
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Several associations were found when the radiographic progression of OA 
was assessed separately for JSN and osteophytes. 
 
 
7.6.1.2. The diagnostic and prognostic values of the cartilage markers if 
radiographic OA progression was expressed separately by osteophytes and 
JSN over two three-year periods 
As the radiographic course of knee OA over six years was non-continuous (see 
the results of the radiographic investigation), the values of the biomarkers were 
assessed separately for the two three-year periods (2002 to 2005 and 2005 to 
2008).  
The values of COMP (assayed at baseline and at the three-year follow-up) 
were associated with progressive osteophytosis over the first three years of 
follow-up (2002–2005), especially in female patients (Table 12). At the same 
time, no association was observed between cartilage markers and JSN in any 
location. 
Quite the opposite was found three years later (2005–2008), when the values 
of another cartilage degradation marker – uCTx-II (assayed at the three- and 
six-year follow-ups) – were associated with progressive JSN in TF, as well as 
the PF compartment (details in Table 12). It seems that the two cartilage 
degradation markers (COMP and CTx-II) reflect different aspects of the early 
process of OA. COMP, reflecting a non-collagenous part of cartilage degra-
dation, seems to respond to the disease earlier in the OA phase, which is 
predominantly expressed by osteophytosis. In summary, both of these markers 
had some diagnostic, as well as prognostic, value for radiographic progression 
of knee OA.  
 
Table 12. Associations between cartilage markers and radiographic progression of OA 




of radiographic features    
First 3 years of follow-up 
Progression of 
radiographic features     
Last 3 years of follow-up 
TF Oph PF Oph TF JSN PFJSN  
COMP at baseline F * n.s. n.s. n.s. 
COMP at 3-yr follow-up M+F *** F * n.s. n.s. 
CTx-II at 3-yr follow-up n.s. n.s. F * M+F ** 
CTx-II at 6-yr follow-up M+F * n.s. M+F * M+F ** 
 
Associations between cartilage markers and radiographic progression of OA features 
were analyzed separately for the two consecutive 3-year periods. 
*  p<0.05, ** p<0.01, ***  p<0.001 by Spearman’s rank correlation.  
Presented data are adjusted for age, BMI and menopausal status 
Abbreviations: 
M – males, F – females 
M+F – males and females together, Oph – osteophytes, JSN – joint space narrowing, 
n.s. – statistically not significant 
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7.6.1.3. The diagnostic and prognostic value of the cartilage markers  
if distinct forms of progressive OA were differentiated 
In the following more detailed analysis, we differentiated between specific 
radiographic subgroups of progressive OA with an isolated progression of only 
JSN (without progressive osteophytosis), of only osteophytes (without pro-
gressive JSN), with progression in only the TF compartment, or with simulta-
neous progression of osteophytes and JSN in several knee joint compartments 
(“extensive progression”). This approach revealed more diagnostic as well as 
prognostic associations between cartilage markers and progressive knee OA.  
 
First three years of follow-up (2002 to 2005):  
The values of all studied cartilage markers – COMP, CTx-II and PIIANP 
(assayed at the three-year follow-up) – were higher in subjects with progressive 
osteophytosis when compared to subjects without OA (Table 13). Serum 
COMP values had a significant positive correlation with isolated TF osteophyte 
progression (cases without JSN; r(s)=0.449, p=0.003; medians in Table 13). 
The uCTx-II values correlated with isolated progression in the TF compartment 
(TF osteophytes in combination with TF JSN; no PF involvement; r(s)=0.411, 
p=0.022; medians in Table 13). As expected, uCTx-II output was higher in 
patients with an extensive progression of OA (i.e. progressive osteophytosis and 
JSN simultaneously in several knee compartments; r(s)=0.415, p=0.004; 
medians in Table 13). The same finding was observed also for sPIIANP 
(r(s)=0.291, p=0.05). Several other associations between the values of sPIIANP 
and radiographic knee OA progression did not remain significant after 
adjustment for age, gender and BMI (data not shown), as sPIIANP had a strong 
correlation with BMI, especially in females (r(s)=0.309, p=0.005).  
 
 
Table 13. Median concentrations of cartilage markers in specific subgroups of radio-
graphic OA progression over 3-year follow-up 
 
Marker * Subgroup of OA progression Progression No OA p value 
sCOMP Isolated TF osteophytes 13.8 (n=16) 11.9 (n=25) 0.003 
uCTx-II Extensive progression † 229 (n=22) 150 (n=25) 0.004 
uCTx-II Isolated TF osteophytes +  TF JSN ‡ 228 (n=6) 150 (n=25) 0.023 
sPIIANP Extensive progression † 758.5 (n=21) 602.7 (n=25) 0.050 
 
The differences in medians between the progressive OA and no OA groups were cal-
culated by Mann-Whitney U-test. 
* Serum and urinary markers assayed at 3-year follow-up. 
† Simultaneous progressive osteophytosis with or without progressive JSN in multiple 
knee joint compartments. 
‡ OA progression only in the TF compartment (TF osteophytes and/or TF JSN), without 
simultaneous PF involvement. 
The numbers in the parentheses represent the number of patients with a distinct type of 
radiographic progression and the number of subjects without radiographic knee OA.  
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According to the above results, all three cartilage markers had some diagnostic 
value for early-stage radiographic knee OA progression. The latter analysis 
offered more precise evidence that progressive osteophytosis is accompanied by 
an enhanced metabolism of articular cartilage.  
 
Subsequent three years of follow-up (2005 to 2008): 
The values of serum COMP and urinary CTx-II, assayed at the three-year 
follow-up (in 2005), had some predictive value for OA progression during the 
subsequent three years (2005–2008). However, the association was limited only 
to the subset of patients with extensive progression of OA (i.e. progressive 
osteophytosis and JSN simultaneously in several knee compartments; for 
COMP r(s)=0.444, p=0.009; n=34; and for CTx-II r(s)=0.408, p=0.016, n=34). 
The median sCOMP values for progressors and non-progressors were 11.9 and 
13.7 U/L, respectively (p=0.016); and for uCTx-II 243 and 172 ng/mmolCrea, 
respectively (p=0.013).  
Significantly increased values of sCOMP and uCTx-II were found in sub-
jects who subsequently developed more severely expressed radiographic OA, 
indicating some predictive value of these biomarkers. At the same time, no 
predictive value for subsequent radiographic knee OA progression was ob-
served for the serum levels of PIIANP.  
 
 
7.6.2. The diagnostic and prognostic value of bone markers in 
radiographic knee OA progression (Paper VI) 
7.6.2.1. Bone markers over a six-year follow-up if knee OA progression was 
expressed by global OA grades  
In general, there was no statistically significant difference in the values of 
studied bone markers (sPINP, sCTx-I, sOC and uMidOC) between the pro-
gressors and non-progressors when we focused only on changes in global OA 
grades (TFOA, PFOA). However, a single exception was noted for the levels of 
sPINP, whose baseline concentrations were significantly higher in subjects who 
developed subsequent simultaneous progression in TFOA and PFOA grades 
over six years; the median concentrations for the progressors and non-pro-
gressors were 59.3 (n=9) and 44.6 (n=21) ng/mL, respectively; p=0.009. A 
significant positive correlation between TFOA+PFOA grade progression and 
baseline values of PINP was also observed (r(s) =0.481, n=30, p=0.008).  
Several associations were found when the radiographic progression of OA 




7.6.2.2. The diagnostic and prognostic values of the bone markers  
if radiographic OA progression was expressed separately  
by osteophytes and JSN  
No statistically significant association was observed between values of bone 
markers and progressive JSN for any knee joint location. However, a significant 
positive correlation was observed between baseline values of sPINP and sub-
sequent progressive TF and PF osteophytosis over the three-year follow-up 
(2002–2005) (r(s)=0.33, n=44, p=0.029). The medians of PINP for the pro-
gressors and non-progressors were 45.2 (n=29) and 39.4 (n=15) ng/mL, respec-
tively; p=0.030. This correlation indicates the prognostic value of the bone 
marker PINP for progressive osteophytosis.  
At the same time, no diagnostic association was observed between values of 
PINP and progressive osteophytosis. In addition, no statistically significant 
diagnostic or prognostic association between values of the other studied bone 
markers, CTx-I, OC and MidOC, and progressive osteophytosis was found.  
 
 
7.6.2.3. The diagnostic and prognostic value of the bone markers if distinct 
forms of progressive OA were differentiated 
In the following analysis, we differentiated between specific radiographic sub-
groups of progressive OA with isolated progression of only JSN (without pro-
gressive osteophytosis), of only osteophytes (without progressive JSN), with 
progression in only the TF compartment, or with simultaneous progression of 
osteophytes and JSN in several knee joint compartments (so called “extensive 
progression”). As already seen for cartilage markers, this approach also revealed 
several diagnostic and prognostic associations between bone markers and 
progressive knee OA.  
 
First three years of follow-up (2002 to 2005): 
Prognostic value: The baseline serum values of PINP were significantly higher 
in the subgroup of patients with more extensive progression of OA compared to 
the “no OA group” (r(s)=0.460, n=35, p=0.005; Table 14).  
Diagnostic value: The serum values of PINP and OC (assayed at the three-
year follow-up, in 2005) had a significant positive correlation with isolated 
progressive TF osteophytosis during the first three years of follow-up (r(s)= 
0.350, n=33, p=0.046 and r(s)=0.458, n=33, p=0.007, respectively). The median 
concentrations of PINP and OC for the osteophyte progressors versus “no OA 
group” are presented in Table 14. A similar association was observed for the 
values of OC (assayed at the three-year follow-up) in subjects in whom disease 
progression was only confined to the TF compartment (TF osteophytes and/or 
TF JSN; without PF involvement; r(s)=0.355, n=42, p=0.007; Table 14).  
At the same time, no statistically significant correlation was observed 
between the values of sCTx-I or uMidOC and the above-described distinct 
forms of progressive knee OA.  
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Table 14. Median concentrations of the bone markers for specific subgroups of radio-




Type of OA 











M + F 58.2 (n=11) 42.3 (n=24) 0.006 Predic-















M + F 26.1 (n=16) 18.6 (n=18) 0.005 
Diag-







M + F 24.5 (n=38) 18.6 (n=13) 0.008 
Diag-
nostic F 24.3 (n=29) 18.1 (n=13) 0.012 
 
Differences in medians between the progressive OA and no OA groups were calculated 
by Mann-Whitney U-test. 
* Simultaneous progressive osteophytosis with or without progressive JSN in multiple 
knee joint compartments. 
† OA progression expressed only by tibiofemoral osteophytes (without simultaneous 
progressive TF JSN or PF involvement) 
‡ OA progression only in the TF compartment (TF osteophytes and/or TF JSN), without 
simultaneous PF involvement. 
The numbers in the parentheses represent the number of patients with a distinct type of 
radiographic progression and the number of subjects without radiographic knee OA.  
 
 
Subsequent three years of follow-up (2005 to 2008): 
Over the following three years, only a single association was found between 
bone markers and progressive knee OA: baseline values of sPINP were posi-
tively correlated with subsequent extensive progression of knee OA (r(s)=0.457, 
n=25, p=0.022). The median values of sPINP for the progressors compared to 
the non-progressors were 58.2 (n=7) and 39.8 (n=18) ng/mL, respectively; 
p=0.013. The latter association again indicates the prognostic value of the bone 
marker PINP for radiographic knee OA progression when the subgrouping of 
the patients was applied. At the same time, no diagnostic value of PINP for 
knee OA progression was observed over the last three years of the follow-up. 
Moreover, no diagnostic or prognostic value of the other bone markers, CTx-I, 
OC and MidOC, was found.  
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7.7. Simultaneous assessment of the associations between 
cartilage and bone biomarkers and knee OA progression 
 
In the present study, an additional statistical computation – logistic regression 
analysis – was performed to quantitatively assess (by odd ratios) the potential 
risk associations between knee OA progression and increasing levels of 
cartilage and bone biomarkers.  
We observed that the risk of isolated TF osteophyte progression was 
significantly increased with the increasing levels of sCOMP, sOC and uMidOC, 
in comparison with the non-progressors (OR=1.41, 95% CI 1.056–1.870, 
p=0.020 for COMP; 1.34, 95% CI 1.05–1.72, p=0.021 for OC and 5.32, 95% CI 
1.41–20.06, p=0.014 for MidOC; Figure 5). These findings demonstrate that, 
among all studied biomarkers, the risk for progressive osteophytosis was 
highest in the case of increased levels of the bone resorption marker uMidOC. 
Increased risk became evident only if a radiographic sub-grouping of patients 
was applied.  
 
 
Figure 5. Associations between biomarker values and progressive tibiofemoral osteo-
phytosis.  
By logistic regression analysis.  
OR – odds ratios; 95 % CI – 95% confidence interval. 
Cartilage and bone markers assayed at 3-year follow-up.  
Progressive tibiofemoral osteophytosis (without simultaneous progressive TF JSN or PF 
involvement) over first three years of follow-up.  
Note that the risk of TF osteophyte progression was significantly increased with the 
increasing levels of sCOMP, sOC and uMidOC, in comparison with the non-pro-
gressors. However, among the studied biomarkers, the risk for progressive osteo-
phytosis was highest in case of the increasing levels of bone resorption marker – 
uMidOC. 
All analyses were adjusted for age, gender, and BMI. 
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The above results are summarized in Table 15 to demonstrate the diagnostic 
and prognostic value of all studied cartilage and bone markers for progressive 
knee OA. The behaviour of biomarkers was clearly different over the six 
follow-up years.  
 
 
Table 15. The diagnostic and prognostic value of cartilage and bone biomarkers for 
radiographic knee OA progression over two 3-year follow-up periods 
 
Biomarker 
First 3 years of follow-up 
(2002–2005) 










sCOMP Yes † Yes * NA Yes † 
UCTx-II Yes † NA Yes ‡ Yes † 
sPIIANP Yes † NA NA NA 
sPINP Yes † Yes * No Yes * 
sOC Yes † No No No 
sCTx-I No  No No No 
uMidOC Yes † No No No 
 
*   Biomarker assayed at baseline (2002) 
†   Biomarker assayed at 3-year follow-up (2005) 
‡   Biomarker assayed at 6-year follow-up (2008)  




All three studied cartilage markers – COMP, CTx-II and PIIANP – expressed 
the diagnostic value for radiographic knee OA progression. Among them, CTx-
II had diagnostic value for progressive OA over both studied time periods (the 
first and last three years of follow-up). Two cartilage markers out of three – 
COMP and CTx-II – had a prognostic value for radiographic knee OA progres-
sion and, of the two, COMP had prognostic value during both studied time 
periods.  
Three bone markers out of four – PINP, OC and MidOC – expressed the 
diagnostic value for progressive knee OA over the first three years of follow-up. 
Interestingly, an association between bone resorption and progressive knee OA 
was observed for the non-collagenous bone resorption marker MidOC, but not 
for the bone collagen (type I) degradation marker CTx-I. Over the last three 
years of follow-up, however, no diagnostic association was observed between 
the studied bone markers and progressive knee OA, which indicates a meta-
bolically non-continuous course of knee OA. This is in accordance with the data 
on the radiographic course of knee OA over six years, which revealed a non-
continuous pattern with periods of progression and intermittent stops. Only one 
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of the studied bone markers, the bone formation marker PINP, had a prognostic 
value for OA progression over both assessed time periods.  
There was, however, no prognostic or diagnostic association between the 






During the past two decades, there have been significant developments in the 
scientific understanding of OA. It is now widely accepted that the OA process 
may arise from any kind of articular tissue: cartilage, subchondral bone, 
synovial tissue, menisci, tendons, ligaments or even periarticular muscles or 
nerves. Moreover, OA is now characterized as a disease with a prolonged 
asymptomatic molecular phase, a pre-radiographic phase and later a radio-
graphic stage, with evident structural joint changes, pain and loss of function 
[49]. Nevertheless, so far the vast majority of studies of OA have been one-
sidedly focused on cartilage changes and conducted on patients with end-stage 
disease. Only a limited number of studies have assessed OA radiographic pre-
valence and its progression in subjects younger than 50 years [61;74;75;124]. 
Thus, the knowledge of the early phases of OA is rather limited.  
In recent years, emphasis has been placed on the development of molecular 
markers that can provide an early warning of the initiation of articular matrix 
breakdown and be used as a method for earlier diagnosis of OA. In previous 
biomarker studies on elderly patients, only single markers originating from 
cartilage or bone tissue have been used separately, which does not offer a full 
overview of the complex metabolic changes in different joint tissues. The 
investigation of OA calls for a simultaneous usage of a whole set of radio-
graphic and non-radiographic means, among them biomarkers originating from 
different joint tissues. The present study is designed largely on the assumption 
of the above understanding.  
In order to achieve a systematic overview of the complex processes of early 
knee OA, a cross-sectional and longitudinal study was performed using 
radiographic and ultrasonographic methods and a full set of molecular markers 
originating from several joint tissues. 
The present study is the first to evaluate the value of an extensive set of joint 
tissue biomarkers in middle-aged subjects with early radiographic knee OA. 
 
Biochemical investigation 
In the present study, we sought to assess whether a set of joint tissue biomarkers 
could differentiate progressive and non-progressive cases of early-stage knee 
OA in middle-aged subjects. To achieve this goal, we simultaneously investi-
gated several aspects of bone and cartilage metabolism cross-sectionally, as 
well as longitudinally, in early stage progressive and non-progressive knee OA. 
We assayed en bloc specific markers of type I collagen synthesis (PINP) and 
resorption (CTx-I), specific markers of type II collagen synthesis (PIIANP) and 
degradation (CTx-II), non-collagenous markers of bone (OC) and a mainly 
cartilage (COMP), as well as a novel non-collagenous, marker of bone 





Specification of the role of the two biomarkers COMP and MidOC  
Although initially considered to be an entirely cartilage-specific molecule 
reflecting cartilage breakdown [89–90], COMP has now been identified in seve-
ral other articular structures, such as synovial capsule, ligaments and tendons. 
However, the concentration of COMP in these tissues is substantially lower 
than that in cartilage and menisci [92–93]. There is even evidence suggesting 
that COMP is also secreted by osteoblasts and vascular smooth muscle cells 
[91]. Our first attempts were therefore devoted to gathering more detailed 
information on the associations between COMP and radiographically assessed 
cartilage damage expressed by JSN, osteophytes and changes in US-detected 
soft tissues in early-stage knee OA. 
We found that serum COMP values were significantly higher in subjects 
with TF osteophytes compared to those without any radiographic disease. In 
addition, the levels of COMP turned out to be substantially affected by the 
changes in knee-joint soft tissues, especially meniscal changes. Therefore, 
compared to other more specific biomarkers, COMP seems to be an even better 
reflector of the changes in the joint, as it consists of the contributions of diffe-
rent articular tissues. These results, which were based on subjects about 20 
years younger than those investigated in earlier studies [113;114;117;120], 
indicate that in early-stage OA, the appearance of osteophytes is accompanied 
by increased serum levels of COMP. Recently, Kraus et al. have even pos-
tulated that COMP is a marker of osteophytes [130]. Our study has therefore 
contributed to the evaluation of the wider role of COMP among other bio-
markers and has clarified its essence. 
A noncollagenous marker OC is synthesized by osteoblasts and has therefore 
been widely used as a biomarker of bone formation [79;111;120]. Its biological 
function is considered to be related to the inhibition of bone matrix 
mineralization [108]. However, total serum OC is a complex marker that 
embraces multiple molecular fragments, some of them associated not only with 
bone synthesis but also with resorption [106–107]. OC fragments accumulating 
in the urine might give qualitatively different information concerning bone 
turnover [107]. It has been previously shown that the urinary mid-molecule 
fragments of OC were suppressed in post-menopausal women with osteoporosis 
who received bisphosphonate alendronate therapy [106;110]. Based on the 
above data, we assumed that molecular forms of OC in urine might not show 
the same characteristics as its mother molecule in serum (total OC). To clarify 
the role of urinary OC, we studied a newly developed marker – MidOC. 
Before implementing this brand new marker in the OA study, we assayed 
MidOC in a small group of post-menopausal women with osteoporosis 
receiving bisphosphonate – risedronate treatment. We assayed MidOC along 
with three other bone markers: serum total OC, PINP and CTx-I. Indeed, we 
observed that the behaviour of MidOC was entirely different from the well 
known bone formation markers total OC and PINP. In fact, quite the opposite 
was found: a parallel decrease was seen in the levels of MidOC and the well-
characterized bone resorption marker sCTx-I after even the first month of 
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risedronate treatment, while the levels of bone formation markers sOC and 
sPINP did not differ from the pre-treatment values at that time point. Moreover, 
during therapy, the strongest correlations were found between the changes in 
MidOC and CTx-I. These results serve as important evidence of MidOC 
behaving similarly to a marker of bone degradation. However, the association 
between MidOC and the bone resorption marker CTx-I was not strong enough 
to assume a complete analogy between these markers. Therefore, in OA, 
MidOC as a noncollagenous marker of bone resorption reflects a different 
aspect of bone degradation. Assuming that MidOC reflects a different aspect of 
bone resorption, we used this new marker in the present early knee OA study. 
To the best of my knowledge, this study is the first to evaluate the role of 
MidOC in knee OA. 
 
Radiographic investigation 
There is limited data on the prevalence of radiographic knee OA in middle-aged 
subjects. According to the few previous studies advanced radiographic knee OA 
(OA grade ≥ 2 by KL or Nagaosa) has been found in 1.5 -14.3% of people aged 
35–54 [3;72;73].  
In the present study, we observed that altogether 56% of the middle-aged 
subjects with chronic knee complaints had radiographic signs of knee OA, the 
majority of them (90%) being diagnosed with knee OA grade 1. It is important 
to mention that in our study as many as 38% of patients with grade 1 OA had 
PF joint involvement alone, mainly due to osteophytosis, highlighting the im-
portance of PF joint assessment. The high prevalence of PFOA among middle-
aged subjects shows the importance of separate assessment of TF and PF joints; 
otherwise, the subjects with early isolated PF joint involvement could easily be 
missed as subjects with no OA or, even worse, could be classified as controls. 
The diagnosis of OA was in more than half of the cases based on the 
presence of osteophytes alone and in one-third of the cases on osteophytes and 
JSN in combination. So, methodically we investigated osteophytosis and JSN as 
different entities of OA. Cross-sectional and longitudinal studies have shown 
that, at least in the knee joint, osteophytes may be a more reliable indicator of 
early disease than a grade 1 JSN [55;58]. In a recent review, V.B. Kraus stated 
that, as osteophytes and JSN involve different pathophysiologies, in biomarker 
studies, analyses of these features should ideally be looked at individually [6]. 
Thus, global KL OA grades may easily dilute the important information of OA 
processes, especially in the subtle early phase. 
In the few previous studies available on middle-aged subjects, the radio-
graphic OA progression has been assessed in different ways, based on either TF 
JSN [75;124] or KL grade [74;124], making it difficult to compare the results of 
different study groups. Thorstensson et al. documented that 86% of middle-
aged subjects with knee pain developed incident TFOA (KL ≥1) over 12 years, 
and incident PFOA occurred in 31% over five years [74]. Single studies 
conducted in subjects as young as in our study have confirmed knee OA 
progression over four and 12 years [75;124]. In the present study, the overall 
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progression rate of early knee OA over six years was 56% (71 out of 128), with 
the majority of cases progressing from grade 0 to 1. The overall OA progression 
rate seemed to be a little lower but compatible with the five-year follow-up data 
by Thorstensson et al. [74]. In almost half of the cases (44%), the radiographic 
progression of OA was based on the development or growth of osteophytes 
alone vs. only in 20% of cases on JSN alone. The separate assessment of osteo-
phytes and JSN in OA prevalence and progression confirmed the importance of 
osteophytosis as the earliest radiographic sign of OA.  
Due to the lack of systematic follow-up data, the natural course of knee OA 
progression has been assumed to be continuous. The study by Sharif et al. was 
the first to indicate the non-linear pattern of knee OA progression over five 
years that was associated with different levels of sCOMP [64]. Indeed, 
following subjects over six years, we observed a radiographically non-consis-
tent course of OA progression, with periods of progression and stabilization. 
Thus, in the majority of OA patients, the radiographic status of knee OA is 
constant or progresses with intermittent stops, being therefore slow, except for a 
few cases with continuous progression. Through longitudinal investigation, we 
observed five different radiographic groups of OA progression, indicating the 
remarkable heterogeneity of the disease. The above findings were largely 
confirmed by the recent study by Bartlett et al. [131], who followed a large 
cohort of OA patients aged 39–80 over two years by JSN and even diffe-
rentiated seven distinct groups of different OA trajectories. In conclusion, both 
of these studies demonstrate that plenty of knee OA patients do not progress 
over two to six years, representing the most common pattern, while the rest 
develop a progressive course at different speeds: slow, moderate or rapid.  
 
Associations between biomarkers and US-detected articular soft tissues 
Although it is now widely accepted that the OA process can be initiated in any 
articular tissue, the importance of soft tissue changes has been clearly 
underestimated. For that reason, there is also a remarkable lack of knowledge 
concerning the potential value of articular biomarkers in the case of OA-related 
soft tissue changes. Jung et al. were the first to investigate the relationship 
between biomarkers and US-detected soft tissue changes in patients with knee 
OA [127]. Their study, which employed relatively few patients, demonstrated 
associations between the levels of general joint tissue biomarkers (HA and 
COMP) and US-detected effusion, synovial proliferation, medial osteophytes 
and capsular distension [127]. To fill the above-described knowledge gap, we 
examined the possible associations between a large set of biomarkers and US-
detected soft tissue changes in early-stage knee OA. To the best of our know-
ledge, this study is the first to investigate associations between US findings and 
biomarkers in middle-aged knee OA subjects. Beside such common US-
detected features as suprapatellar effusion, synovial thickening, meniscal chan-
ges and Baker`s cysts, the presence of calcifications in the quadriceps and 
patellar tendons were documented – an aspect that seems to have been over-
looked.  
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We succeeded in demonstrating several significant associations between bio-
markers and US-detected soft tissue changes. Our results confirmed that in 
patients with early-stage knee OA US-detected soft tissue changes play a major 
role in the overall variability of bone and cartilage biomarkers. At the same 
time, the observed diverse links between biomarkers and soft tissue changes 
indicated the remarkable complexity of the OA metabolic processes in knee 
joint soft tissues. Moreover, the findings turned out to be substantially in-
fluenced by gender differences and in females also by menopausal status. In 
pre-menopausal women, US-detected synovitis was related to the increased 
synthesis of type I collagen (as shown by PINP) and the decreased expression of 
type II collagen (by PIIANP). The latter shifts seem to indicate that the presence 
of synovitis probably retards the synthesis of articular cartilage. Some features 
of synovitis, such as thickening of the synovial layer and the presence of 
Baker’s cysts, predicted up to 20% of the variability of bone marker sPINP. As 
a considerable part of synovial tissue consists of type I collagen, the activation 
of synthetic processes in synovium might be responsible for the higher serum 
levels of PINP [132]. Surprisingly, several associations were observed between 
biomarkers and the presence of tendon calcifications. In women, all three bone 
markers – PINP, CTx-I and OC – were associated with quadriceps tendon 
calcifications. As type I collagen is the major collagen in tendons [133], these 
metabolic markers may indicate ongoing active metabolic changes in tendons. 
On the other hand, in post-menopausal women, patellar tendon calcifications 
were strongly correlated with cartilage degradation (by uCTx-II) but not with 
cartilage synthesis (by sPIIANP). These findings, however, suggest that tendon 
calcifications accompany the active degradation processes in articular cartilage. 
The presence of tendon calcification seemed to signal a phase of knee OA with 
simultaneous activation of metabolic changes in bone and soft tissue meta-
bolism but degradation in articular cartilage. These diverse findings have never 
been described before. In men, quite the opposite was observed: tendon 
calcifications were related to cartilage synthesis (based on PIIANP) but not to 
cartilage degradation (based on CTx-II), suggesting that, in the case of tendon 
calcification, there is a strong predilection for the production of type II collagen. 
Hence, in early-stage knee OA the presence of tendon calcifications might 
indicate the predominance of cartilage reparation in men and cartilage degra-
dation in women. Tendon calcifications made it possible to predict up to 35% of 
the variability in CTx-II and up to 38% of the variability of PIIANP, in women 
and men, respectively.   
In females, suprapatellar effusion, meniscal changes and subchondral con-
tour defects together predicted up to 29% of the variability of sCOMP. This 
finding served as additional evidence for the point of view that, besides 
cartilage degradation, the level of sCOMP is substantially influenced by chan-
ges in soft tissues.  
The above findings enable us to conclude that a wide-ranging set of articular 
biomarkers, such as COMP, CTx-II, PIIANP and PINP, is certainly necessary to 
have an overview of the ongoing complicated processes in articular tissues 
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during OA.  US seemed to offer definite, unique and clinically easily available 
information on the complex processes in articular soft tissues in early-stage 
knee OA. 
 
Associations between cartilage biomarkers and radiographic knee OA 
progression  
The vast majority of cartilage biomarker studies on OA progression have 
focused on elderly subjects with advanced-stage disease [112;114;117;119–
121]. The limited number of studies conducted on middle-aged subjects has 
shown that cartilage biomarkers seem to have both diagnostic [122] and 
prognostic [123–124] roles in early-stage knee OA. However, the above studies 
have investigated only a single aspect of OA cartilage metabolism by IGF-1 
[123], COMP [122] or PIICP [124], whereas a simultaneous assessment of the 
synthesis and degradation of cartilage has not been addressed. In these studies, 
the follow-up period was long enough – three to 12 years – but only two time 
points were registered: baseline and endpoint. The above-described approach 
does not make it possible to explore the non-linear course of OA, which is 
present according to recent studies.  
It is clear, that the complexity of the early OA processes calls for more 
extensive studies and a systematic approach. To gain a more comprehensive 
overview of early-stage OA, we assayed cartilage biomarkers reflecting both 
sides of the metabolism: synthesis and resorption of cartilage (type II), collagen 
(PIIANP and CTx-II, respectively) and a noncollagenous marker of articular 
tissues that is presumed to signal mainly cartilage degradation, COMP.  
As described above, following each subject radiographically over six years, 
a non-consistent course of OA radiographic progression was observed. There-
fore, the duration of the present biomarker study was divided into two con-
secutive three-year periods – the first three years and the last three years of 
follow-up (i.e. 2002 to 2005 and 2005 to 2008). 
The associations between cartilage biomarkers and the presence of radio-
graphic knee OA features examined at three different time points (at baseline, 
three- and six-year follow-ups) were different over the course of six years and 
largely dependent on gender, age, the phase of OA development and OA 
radiographic features (osteophytes or JSN). The presence of TF osteophytes was 
reflected by increased cartilage degradation (by COMP and CTx-II). At the 
same time, the thinning of articular cartilage in TF as well as in PF joints was 
associated with a decrease in cartilage synthesis (by PIIANP). A similar finding 
was observed by Garnero et al. in elderly patients with advanced TF JSN [116]. 
Thus, at the group level, lower values of PIIANP signal the presence of 
cartilage damage both in early and advanced cases of knee OA. 
So far, radiographic knee OA progression has been diagnosed based on the 
thinning of JSW or on the increase in global KL grade. These criteria, however, 
overlook the first radiographic sign of early OA – osteophytosis. Separate 
assessment of osteophytes and JSN enabled us to reveal a certain pattern of 
metabolic shifts in the course of progressive knee OA. Over the first three years 
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of follow-up, we observed a significant correlation between COMP and pro-
gressive osteophytosis, whereas over the subsequent three years the correlation 
was between CTx-II and progressive JSN. These results indicate that these two 
markers of cartilage degradation (COMP and CTx-II) reflect different aspects of 
the early OA. COMP, reflecting a noncollagenous part of cartilage degradation, 
seems to respond to the disease earlier in the period, predominantly expressed 
as progressive osteophytosis. The phase of progressive osteophytosis seems to 
be followed by a more advanced disease, expressed by progressive cartilage 
damage, reflected by the higher output of uCTx-II. Thus, the described bio-
chemical processes in OA-affected articular tissues serve as more evidence of 
the complex course of the disease. 
We observed that the values of all studied cartilage markers – COMP, CTx-
II and PIIANP – were higher among the subgroup of subjects with progressive 
osteophytosis when compared to subjects without OA. According to the detailed 
analysis, serum COMP values were higher in the case of subtle OA changes: 
isolated progressive osteophytosis only in the TF compartment (cases without 
JSN and PF involvement). On the other hand, the uCTx-II values were higher in 
more extensive cases of progression, such as progression in the TF compart-
ment (progressive TF osteophytosis + TF JSN in combination) or progressive 
OA (osteophytosis + JSN) simultaneously in several knee compartments. The 
latter association was also true for sPIIANP. Several associations between the 
values of sPIIANP and radiographic knee OA progression, however, did not 
remain significant after adjustment for age, gender and BMI, as sPIIANP had a 
strong correlation with BMI, especially in females. To the best of our know-
ledge, this is the first attempt to describe the activation of cartilage metabolism 
in early progressive knee OA.  
It is known that osteophytes represent areas of new cartilage and bone 
formation [134]. Osteophyte formation starts with chondrogenesis within 
fibrous mesenchymal tissue, which then results in a cartilage-like structure 
called a chondrophyte (fibrocartilaginous cells). The core of the chondrophyte 
undergoes hypertrophy, followed by ossification (chondro-osteophyte). Even-
tually, the entire structure turns into bone (osteophyte) [36]. As described 
above, in the present cohort, progressive osteophytosis was associated with en-
hanced turnover in both the collagenous and noncollagenous components of 
cartilage (based on uCTx-II, sCOMP and sPIIANP). We propose several pos-
sible explanations for the associations between progressive osteophytosis and 
cartilage biomarkers (Paper V). First, during the formation of a stage III osteo-
phyte, it consists of aggrecan, collagen type II and even chondrocytes [35]. 
Therefore, during progressive osteophytosis, the products of cartilage meta-
bolism (uCTx-II, sPIIANP and sCOMP) may be released into the systemic 
circulation in higher concentrations. The serum pool of COMP might also 
indicate changes in soft tissues (meniscal changes) or reflect enhanced osteo-
blastic activity in the chondro-osteophytic stage of osteophyte development 
[135]. As a more direct explanation, according to some MRI studies, knee 
cartilage defects may accompany radiographically detected osteophytes of the 
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same joint, either indirectly [136] or causally [63]. Therefore, the increase in 
cartilage degradation (by uCTx-II and sCOMP) in progressive osteophytosis 
might indicate accompanying defects in articular cartilage not yet visible 
through plain radiography.  
According to the BIPED criteria, biomarkers are presumed to have five 
different categories of performance, among them a diagnostic and prognostic 
one [82]. Following the above criteria, all three cartilage biomarkers used in the 
present study have been shown to be prognostic markers of knee OA 
progression in elderly patients [117–119]. In the present study, serum COMP 
and urinary CTx-II concentrations, assayed at the three-year follow-up, had 
some predictive value for OA progression during the subsequent three years. 
However, the association was limited only to the subset of patients who 
demonstrated a more extensive knee OA progression (osteophytosis+JSN) 
simultaneously in different knee joint compartments. As a result, sCOMP and 
uCTx-II had some predictive value, although only in subjects who subsequently 
developed more severely expressed radiographic features of OA. 
The results of the present study enable us to conclude that all three studied 
cartilage biomarkers, CTx-II, PIIANP and COMP, had a diagnostic role for OA 
progression (mainly expressed by progressive osteophytosis) and two of them, 
COMP and CTx-II, also had some predictive value for subsequent OA pro-
gression if there was more extensive knee OA progression (osteophytosis+JSN) 
simultaneously in different knee compartments. The predictive potential of 
cartilage markers was therefore clearly expressed only among some radio-
graphic subgroups. This study confirms the view that separate assessment of 
osteophytosis and JSN as different entities of OA is crucially important in 
biomarker studies. During early phases of OA, distinct metabolic pathways of 
articular tissues were activated, especially those associated with the presence 
and progression of osteophytosis.  
 
Associations between bone biomarkers and radiographic knee OA 
progression  
Two decades ago it was suggested that changes in bone rather than cartilage 
might be responsible for the initial pathophysiological events in OA [30–31;33]. 
Nevertheless, so far, bone involvement has received inadequate attention in 
human OA. Studies on bone turnover markers have been focused on elderly 
patients with advanced-stage knee OA and provided rather conflicting data. 
Cross-sectional studies have revealed a decrease in bone resorption (by sCTx-I 
and uCTx-I) and mineralization (by sOC) [79], or no change at all [111;115; 
120]. Thus, so far, it is unclear whether OA is characterized by increased 
[62;94;122,137] or decreased [79;119] bone turnover. In a longitudinal study by 
Bettica et al., bone resorption was higher in post-menopausal women with 
progressive knee OA when compared to controls [62], indicating the possible 
prognostic value of these markers. 
Previous studies have mainly focused on bone resorption markers reflecting 
degradation of type I collagen (CTx-I and NTx-I). At the same time, the other 
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aspect of bone turnover – synthesis of bone collagen (by the levels of PINP) – 
has not been routinely assessed. Instead of PINP, serum levels of a non-
collagenous marker, OC, have been assayed as a measure of bone formation 
[79;111;120]. However, as OC is a complex marker that embraces molecular 
fragments also reflecting bone resorption and inhibition of bone matrix 
mineralization [108], it should not be regarded as a marker of merely bone 
formation (i.e. as an equivalent to PINP). 
In the present study, we investigated simultaneously the synthetic, resorptive 
and mineralization aspects of bone metabolism in early-stage progressive and 
non-progressive knee OA. To achieve this, we assayed en bloc specific markers 
of type I collagen synthesis (PINP) and resorption (CTx-I), as well as a non-
collagenous marker, OC, and a novel noncollagenous marker of bone 
resorption, MidOC. 
Our results on the associations between bone marker values and progressive 
radiographic knee OA again supported the view that global knee OA grades fail 
to reveal important information about the OA process. Indeed, when we used 
global radiographic OA grades, only a single positive correlation was observed 
between six-year progression in TFOA+PFOA grade and higher serum values 
of PINP. However, when different OA features – JSN and osteophytes – were 
analyzed separately and some radiographic forms of progressive knee OA were 
differentiated, we were able to demonstrate several diagnostic and prognostic 
values of the bone markers for progressive knee OA. We established that pro-
gressive TF osteophytosis was accompanied by the activation of bone formation 
(by PINP), bone resorption (by MidOC), and by changes in bone mineralization 
(by OC), providing evidence of the diagnostic value of these biomarkers. It is 
important to note that the association between progressive osteophytosis and 
bone resorption was reflected only by the novel noncollagenous marker MidOC, 
and not by the well-known collagen type I degradation marker CTx-I. This 
discrepancy between the two bone resorption markers indicates that these bio-
markers represent qualitatively different aspects of bone resorption. Based on 
these results, we can speculate that the course of knee OA is comprised of a 
certain sequence of events. Changes in bone formation and mineralization, as 
well as in the degradation of the noncollagenous part of bone, precede the 
collagenous side of bone degradation. However, this hypothesis needs further 
clarification through larger experimental and clinical material. 
Interestingly, three years from baseline, no diagnostic association was ob-
served between the above bone markers and progressive OA, indicating a meta-
bolically non-continuous course of knee OA. This finding is in accordance with 
our six-year radiographic data from the same cohort, which revealed a non-
continuous course of knee OA, with periods of progression and stabilization. 
Moreover, radiographically, markedly fewer cases of OA progression were 
found over the first three years of follow-up when compared to the last three 
years. Thus, we established a metabolically and radiographically non-conti-
nuous course of knee OA. In the second period of follow-up, we observed fewer 
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cases of radiographic progression, as well as lower metabolic activity of bone 
tissue.    
In our material, progressive osteophytosis, as well as more extensive knee 
OA progression (i.e. combined progression in several knee compartments, 
including both osteophytes and JSN), was preceded by the activation of the 
synthesis of type I collagen expressed by serum PINP. This finding provides 
evidence of the prognostic value of PINP for progressive knee OA. At the same 
time, no prognostic value was found for the other bone markers: OC, CTx-I and 
MidOC. The enhanced synthesis of type I collagen (by PINP) possibly reflects 
the activation of reparative processes in early-stage knee OA. At the same time, 
the resorptive activity was only modest and there was no prognostic association 
between the bone resorption markers and progressive knee OA. Later, when the 
disease had progressed, enhanced bone resorption became evident.  
As already observed for cartilage markers, several associations between 
bone markers and progressive osteophytosis were found. There are at least two 
possible explanations for the associations between progressive osteophytosis 
and higher levels of bone markers. Firstly, the higher levels of bone markers, 
especially bone formation markers, presumably reflect the ossification stage of 
osteophyte formation. Secondly, higher levels of PINP, a marker of type I 
collagen that is present also in soft tissues, e.g. mensici, ligaments and tendons, 
might also reflect changes in soft tissues (meniscal changes) that might ac-
company progressive osteophytosis. 
Thus, our findings from patients with early radiographic knee OA de-
monstrate the activation of bone metabolism in the case of progressive disease. 
Prior to radiographic knee OA progression, we observed an activation of 
reparative processes in bone (bone formation by PINP), which eventually turned 
out to be inefficient. Later, we documented radiographic OA progression, which 
was accompanied by an activation of all aspects of bone turnover (by PINP, OC 
and MidOC). Resorption of the noncollagenous bone (by MidOC) seems to be 
enhanced before the degradation of collagen type I (by CTx-I).   
Three of the studied bone markers (PINP, OC and MidOC) had diagnostic 
value for progressive osteophytosis, and one of them, PINP, had prognostic 
value for progressive osteophytosis, as well as for more extensive cases of OA 
progression (simultaneous progressive osteophytosis + JSN in several knee 
compartments). 
 
Surprisingly, there is no previous knee OA study available that has systemically 
evaluated the possible value of cartilage and bone biomarkers simultaneously 
on the same material, except for a single study by Petersson et al. conducted in 
1998 [122]. In this study, it was found that the cartilage marker COMP and 
bone marker BSP were both associated with incident radiographic knee OA.  
Based on the results of logistic regression analysis, we established that 
increasing values of the cartilage marker COMP, as well as the bone markers 
OC and MidOC, were significantly associated with an increased risk for pro-
gressive TF osteophytosis when compared to subjects without radiographic evi-
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dence of knee OA. It seems reasonable to assume that OA is a disease affecting 
mainly articular cartilage and may be better reflected by changes in cartilage 
biomarkers. However, a comparison of the odd ratios of COMP and MidOC for 
predicting progressive osteophytosis (OR 1.41 vs. 5.32, respectively) allowed us 
to conclude that in early-stage knee OA changes in bone metabolism are not 
only present but can even dominate over changes in cartilage. To the best of our 
knowledge, the present study was the first to investigate the value of the novel 
bone resorption marker MidOC in knee OA – a marker that, among all other 






The present study offered several new insights into the complex early phases of 
knee OA and proposed a possible sequence of metabolic events in joint tissues 
during the early phases.  
We demonstrated that more than half of the middle-aged subjects with knee 
joint complaints had radiographically evident knee OA. The longitudinal study 
revealed that the overall progression rate of early-stage knee OA was 56%, with 
the majority of cases progressing from grade 0 to grade 1, and they were largely 
based on osteophytosis.  
We established that, during early phases of OA, distinct metabolic pathways 
of articular tissues were activated, especially those associated with the presence 
and progression of osteophytosis. Separate assessment of osteophytes and JSN 
enabled us to reveal a certain pattern of shifts in cartilage and bone metabolism 
in the course of progressive knee OA.  
A noncollagenous cartilage degradation (reflected by COMP) seems to 
develop earlier in the disease, in a period predominantly expressed as progres-
sive osteophytosis. The phase of progressive osteophytosis seems to be 
followed by a more advanced disease, expressed by progressive cartilage 
damage, reflected by the higher output of uCTx-II. Thus, these two markers of 
cartilage degradation (COMP and CTx-II) signal different aspects of the early 
OA process.  
Prior to radiographic knee OA progression, we observed an activation of 
reparative processes in bone (by PINP) that eventually turned out to be in-
efficient. The phase of inefficient bone reparation was followed by shifts in all 
aspects of bone turnover: activation of synthesis and degradation (by PINP and 
MidOC), as well as by changes in bone mineralization (by OC). However, the 
resorption of nonocollagenous bone (by MidOC) seems to be enhanced before 
the degradation of collagen type I (by CTx-I).   
We observed a radiographically and metabolically non-continuous course of 
knee OA over six years. In the second period of follow-up (the last three years 
of follow-up), we observed fewer cases of radiographic progression, as well as 
lower metabolic activity in cartilage and bone tissue.   
The present study is the first to demonstrate that, in early-stage knee OA, the 
metabolism of bone, cartilage and soft tissues was simultaneously activated. 
Although initially considered to be a disease affecting mainly articular cartilage, 
our results indicate that, at least in early-stage knee OA, the changes in bone 
metabolism may even dominate over that of cartilage. Moreover, we observed a 
surprisingly important contribution of ultrasonographically detected soft tissue 
changes to the systemic value of all studied cartilage markers (COMP, CTx-II 
and PIIANP) and of the bone marker PINP.   
 
We discovered that all three studied cartilage markers (COMP, CTx-II and 
PIIANP) had diagnostic value for progressive osteophytosis, and two of them 
(COMP and CTx-II) also had prognostic roles for progressive osteophytosis and 
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JSN. At the same time, three of the studied bone markers (PINP, OC and 
MidOC) had diagnostic value, again for progressive osteophytosis, and one of 
them, PINP, demonstrated a predictive value for more extensive cases of OA 
progression (osteophytosis + JSN simultaneously in several knee compart-
ments). We specified the resorptive origin of the novel bone marker MidOC, 
which among all other studied biomarkers turned out to be the strongest risk 
predictor for progressive osteophytosis.  
Based on the findings of the present study, we can offer some recommen-
dations for future OA investigations: (i) the complex nature of knee OA calls 
for a multifaceted methodical approach, including simultaneous biochemical 
and radiologic assessment of the changes in bone, cartilage and soft tissues; (ii) 
the status of osteophytes and JSN must be examined separately, as they indicate 
different phases of OA, and the presence/progression of which are likely to be 
reflected by different biomarkers; (iii) the impact of gender should be carefully 
evaluated; (iv) some bone and cartilage biomarkers may be used in early knee 
OA to evaluate the diagnostic or prognostic value for knee OA, mainly for pro-
gressive osteophytosis; (v) as early knee OA revealed its non-continuous course 
radiographically, as well as biochemically, more than two time points should be 





 The present study is the first to demonstrate the simultaneous activation of 
cartilage, bone and soft tissue metabolism in early-phase knee OA.  
 At least in early-stage knee OA, the changes in bone metabolism may even 
dominate over that of cartilage. The latter conclusion is based on the finding 
that, among all studied biomarkers, a novel marker of bone resorption – 
MidOC – appeared to be the strongest risk predictor of progressive osteo-
phytosis.  
 COMP, as a predominantly cartilage-specific biomarker, is substantially 
reflected by the presence and growth of osteophytes and changes in knee 
joint soft tissues, especially in menisci. Therefore, we confirm the view that 
COMP reflects the systemic contribution of different articular tissues.  
 More than half (56%) of the middle-aged subjects with chronic knee 
complaints had radiographic knee OA, and in the majority of cases OA grade 
1. The progression rate of radiographic knee OA over six years was 56%, 
with the majority of cases based on osteophytosis. The radiographic course 
of early knee OA turned out to be heterogeneous and non-continuous, with 
intermittent periods of progression and stabilization. 
 Ultrasonographically detected soft tissue changes were common in early-
stage knee OA, and among these the most prevalent findings were calcifi-
cation in the patellar and quadriceps tendons, synovial thickening, supra-
patellar effusion, Baker’s cysts and meniscal changes. The variability of 
articular biomarker values was substantially influenced by the accompanying 
US-detectable changes in joint soft tissues:  
–  The presence of tendon calcifications was accompanied by cartilage 
reparation (by  PIIANP) in men and cartilage degradation (by CTx-II) in 
women.  
–  In women, US-detected findings of synovitis were simultaneously related 
to the increased synthesis of type I collagen (by PINP) and the decreased 
expression of type II collagen (by PIIANP), indicating that the presence 
of synovitis probably retards the synthesis of articular cartilage. 
 The present study revealed a certain pattern of shifts in cartilage and bone 
metabolism over the course of progressive knee OA:  
–  Higher serum values of the noncollagenous cartilage degradation marker 
COMP reflected the earlier disease period predominantly expressed by 
progressive osteophytosis, which was followed by more advanced 
disease, expressed by JSN, reflected by a higher level of uCTx-II. 
–  Radiographic knee OA progression was preceded by activated bone 
reparation (by PINP) and followed by activation of all aspects of bone 
turnover: synthesis of collagen type I (by PINP), degradation of non-
collagenous bone (by MidOC) and changes in bone mineralization (by 
OC).           
 All three studied cartilage biomarkers, COMP, CTx-II and PIIANP, had 
diagnostic value for progressive osteophytosis and two of them, COMP and 
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CTx-II, also had some predictive role for subsequent more extensive OA 
progression (osteophytosis and JSN in combination). 
 Three of the studied bone markers, PINP, OC and MidOC, had diagnostic 
value for progressive osteophytosis, and one of them, PINP, also had 
predictive role for subsequent more extensive OA progression subsequent 
more extensive OA progression.  
 The present study demonstrated that the complex nature of knee OA calls for 
a multifaceted methodical approach including: (i) biochemical and radio-
logic assessment of the simultaneous changes in bone, cartilage and soft 
tissues; (ii) evaluation of the impact of gender and different phases of the 
disease; (iii) separate assessment of OA radiographic features, osteophytes 
and JSN, the presence/ progression of which are likely to be reflected by 
different biomarkers; and (iv) the assessment of more than two time points in 
longitudinal studies, as early OA has a non-consistent course radio-






























11. SUMMARY IN ESTONIAN 
 
Liigeskudede molekulaarsed markerid põlveliigese varase 
osteoartroosi korral: rahvastikupõhine longitudinaalne  




1. Uurida, milliseid metaboolseid protsesse ja muutusi põlveliigese kudedes 
peegeldavad seerumist määratav kõhre oligomeetriline maatriksproteiin 
(COMP) ja uus luukoe päritoluga biomarker – uriini ostekaltsiini keskfrag-
ment (MidOC).  
2. Hinnata põlveliigese röntgenoloogilise osteoartroosi (OA) levimust ja 
progressiooni  keskealistel põlveliigese kaebustega isikutel. 
3. Selgitada võimalikke seoseid kõhre- ja luukoe päritoluga molekulaarsete 
markerite ja ultraheli uuringul hinnatavate liigeskudede muutuste vahel 
varases staadiumis OA haigetel.  
4. Analüüsida kõhrekoe molekulaarsete markerite diagnostilist ja ennustavat 
väärtust põlveliigese OA progresseeruvatel juhtudel.  
5. Analüüsida luukoe molekulaarsete markerite diagnostilist ja ennustavat 
väärtust põlveliigese OA progresseeruvatel juhtudel.  
 
 
Uuritavad ja meetodid 
 
Krooniliste põlvekaebustega (kestusega > 3 kuu) uuritavad vanuses 34–55 
aastat leiti Elva perearsti nimistu alusel. Ankeedile vastanud 348-st inimesest 
osales lõplikus longitudinaalses uuringus 161 isikut (101 naist ja 60 meest, 
keskmine vanus 45,0 ± 6,2 a.). Uuringud teostati kolmel järjestikusel ajapunktil, 
uuringu algul (2002 a.), keskel (2005 a.) ja lõpus (2008 a.).  
Uuringus nõustus osalema 73 liigeskaebusteta isikut. Neist 40 isikut, kel 
puudusid röntgenoloogilised põlveliigese OA tunnused (25 naist ja 15 meest), 
hõlmati kontrollgrupina.  
Uue biomarkeri – osteokaltsiini keskfragmendi (MidOC) olemuse uuri-
miseks hõlmati 19 postmenopausis osteoporoosiga naist vanuses 49–66 a., kes 
said 12 kuu jooksul ravi bisfosfonaat- risedronaadiga. Luukoe päritoluga mole-
kulaarsete markerite käitumist (sh. MidOC korral) uuriti seoses luu mineraalse 
tiheduse muutustega vastuseks ravile.  
OA röntgenoloogilisi tunnuseid (osteofüüte ja liigesvahemiku kitsenemist) 
uuriti kõigis kolmes ajapunktis nii põlveliigese tibiofemoraalses (TF) kui 
patellofemoraalses (PF) osas. Liigesvahemiku kitsenemist (LVK) ning oste-
ofütoosi hinnati nelja-astmelisel skaalal vastavalt Nagaosa ja tema kaastöötajate 
hindamissüsteemile [56]. Röntgenoloogilist progressiooni defineeriti kui: (i) 
osteofüütide või LVK kujunemist isikutel, kel eelneval uuringul OA tunnuseid 
puudusid, või (ii)  olemasolevate osteofüütide ja LVK astme ja/või arvu suure-
nemist jälgimisperioodi jooksul. 
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Ultraheli (UH) uuringud teostati kasutades mitmesageduslikku 7,5 MHz 
lineaarandurit. Osteofüütide ja Baker`i tsüstide olemasolu, kõõluste ja kõhrekoe 
läbimõõtu, meniskide muutusi,  sünoviaalset hüperperfusiooni ja liigesefusiooni 
registreeriti vastavalt EULAR juhistele ning hinnati kaheastmelisel skaalal 
[128]. Lisaks eelnevatele dokumenteeriti uue lähenemisena ka kõõluste lubjas-
tumiste ning subkondraalse luu kontuuri defektide olemasolu. Ultraheli 
uuringud teostati kokku 106 isikul (73 naisel ja 33 mehel).  
Materjal (seerum ja uriin) laboratoorseteks määramisteks koguti kõigis 
kolmes ajapunktis.  
Kõhrekoe sünteesi hinnati seerumi II A tüüpi prokollageeni amino-termi-
naalse propeptiidi (sPIIANP), lammutamist – uriini II tüüpi kollageeni C-
terminaalse telopeptiidi fragmentide (uCTx-II) ning seerumi kõhre oligo-
meetrilise maatriksproteiini (sCOMP) väärtuste alusel ELISA meetodil. 
Luukoe sünteesi hinnati seerumi I tüüpi prokollageeni amino-terminaalse 
propetiidi (sPINP), mineralisatsiooni – osteokaltsiini (sOC) ning lammutamist I 
tüüpi kollageeni C-terminaalse telopeptiidi (sCTx-I) väärtuste alusel rakendades 
elektrokemiluminestsentsmetoodikat.  
Uut luukoe päritoluga biomarkerit – uriini osteokaltsiini keskfragmenti 
(uMidOC) määrati ELISA meetodil.  
Statistiliseks andmetöötluseks kasutati mitteparameetrilisi meetodeid (Spear-
man’i astakkorrelatsiooni, Mann-Whitney U-testi). Tulemused kohandati 
vanuse, KMI, menopausist tulenevate mõjude suhtes kasutades osakorrelat-
siooni. Kuna biomarkerite väärtused on suures osas soost sõltuvad, hinnati mehi 
ning naisi enamikel juhtudel eraldi. Seoseid biomarkerite väärtuste ja OA 
röntgenoloogiliste tunnuste vahel hinnati Spearmani astakkorrelatsioonide 
alusel. Biomarkerite diagnostilist ja prognostilist väärtust röntgenoloogilise 
progresseerumise juhtudel võrreldes mitte-progresseerujatega hinnati Mann-
Whitney U-testi alusel. Biomarkeri seerumi- või uriinikontsentratsiooni muu-
tuse seost OA röntgenoloogilise progresseerumisega võrreldes mitteprogressee-
ruvate juhtudega (šansside suhe) hinnati rakendades logistilist regressioon-
analüüsi. Mitmene regressioonanalüüs oli kasutusel hindamaks ulraheli alusel 
leitud pehmete kudede muutuste rolli biomarkerite väärtuste variaabelsuses.  
 
       
Tulemused ja järeldused 
 
1. Käesoleva uurimusega õnnestus esmakordselt näidata, et OA varases faasis 
on samaaegselt aktiveeritud nii kõhre-, luu- kui ka pehmete kudede aine-
vahetus. 
2. Vähemalt OA algfaasis võivad luukoe ainevahetuse muutused isegi domi-
neerida kõhrekoe haaratuse üle. Uuritud biomarkerite seas osutus luukoe 
lammutamise uus marker, MidOC, tugevaimaks riski ennustajaks osteo-
füütide progressiooni suhtes.   
3. COMP`i kui valdavalt kõhrespetsiifilise biomarkeri kontsentratsioon see-
rumis oli oluliselt mõjutatud osteofüütide kujunemise ja kasvu ning pehmete 
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kudede (eeskätt meniskide) muutuste poolt. Käesolev töö kinnitas, et COMP 
on üldine liigeskudede biomarker, mis on üheaegselt mõjutatud mitmete 
erinevate liigeskudede muutuste poolt.  
4. Põlveliigeste ultraheli-uuringutel hinnatavate pehmete kudede muutused olid 
levinud OA varases staadiumis, sagedamini leiti kõõluste lubjastumist, süno-
viaalkoe paksenemist, suprapatellaarset efusiooni, Baker’i tsüste ja menis-
kide muutusi. Liigese pehmete kudede ainevahetuse muutused mõjutavad 
märkimisväärselt biomarkerite kontsentrat-sioone vereseerumis ja uriinis.   
–  Kõõluste lubjastumisega kaasnes meestel kõhrekoe sünteesi aktiveeru-
mine (PIIANP alusel) ning naistel selle lammutamine (CTx-II alusel). 
– Naistel kaasnes sünoviidiga I tüüpi kollageeni sünteesi aktivatsioon 
(PINP alusel) ja II tüüpi kollageeni sünteesi vähenemine (PIIANP alusel), 
mis viitab sünoviidi pärssivale mõjule kõhre sünteesil.  
5. Rohkem kui pooltel (56%) põlvevaevustega keskealistest inimestest esinesid 
OA röntgenoloogilised tunnused. Kuue jälgimisaasta jooksul süvenes haigus 
56% uuritutest, enamikel juhtudel progresseeruva osteofütoosina. Põlve-
liigese varase OA röntgenoloogiline kulg oli heterogeenne ja mittepidev, 
hõlmates vahelduvalt haiguse stabiliseerumise ja süvenemise perioode.   
6. Käesoleva uurimusega õnnestus selgitada liigeskudede ainevahetuse muu-
tuste iseloomulikku mustrit OA varase progresseerumise juhtudel:  
–  Mittekollageense kõhrekoe lammutamine (COMP alusel) oli aktiveeritud 
just OA varases staadiumis, mida valdavalt iseloomustas süvenev osteo-
fütoos. Sellele järgnes II tüüpi kollageeni lammutamine (CTx-II alusel), 
mida röntgenoloogiliselt iseloomustas süvenev LVK. Need kõhrekoe bio-
markerid esindavad seega haiguse erinevaid staadiume.  
–  OA röntgenoloogilisele progressioonile eelnes luu sünteesi aktivatsioon 
(PINP alusel) ja järgnes luukoe sünteesi (PINP alusel) ja mittekolla-
geense luukoe lammutamise (MidOC alusel) aktivatsioon ning minerali-
satsiooni muutused (OC alusel). 
7. Osteofütoosi süvenemisega kaasnes kõhrekoe sünteesi (PIIANP alusel) ja 
lammutamise (CTx-II ja COMP alusel) aktivatsioon, samas kui OA 
laialdasemale progressioonile (osteofütoos ja LVK kombinatsioonis) eelnes 
kõhrekoe lammutamise suurenemine (CTx-II ja COMP alusel). Seega, kõik 
kolm uuritud kõhrekoe biomarkerit omasid diagnostilist väärtust progres-
seeruva osteofütoosi suhtes, ning kaks neist, COMP ja CTx-II, samuti 
ennustavat rolli laialdasema OA progressiooni suhtes (osteofütoos ja LVK 
samaaegselt mitmes põlveliigese lokalisatsioonis).  
8. Osteofütoosi süvenemisega kaasnes luukoe sünteesi aktiveerumine (PINP 
alusel), mittekollageense luukoe lammutamine (MidOC alusel) ja muutused 
luukoe mineralisatsioonis (OC alusel), samas kui OA laialdasemale 
progressioonile (osteofütoos ja LVK kombinatsioonis) eelnes I tüüpi kolla-
geeni sünteesi kiirenemine (PINP alusel). Kolm uuritud luumarkerit neljast, 
PINP, OC ja MidOC, omasid diagnostilist väärtust progresseeruva osteo-
fütoosi suhtes, ja üks neist, PINP, samuti ennustavat rolli OA laialdasema 
progressiooni juhtudel.  
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9. Käesoleva uuringu alusel võib järeldada, et põlveliigese OA keerukas 
olemus nõuab mitmetahulist metoodilist lähenemist, sealhulgas: (i) liiges-
kõhre, luu- ja pehmete kudede biokeemiliste ja radioloogiliste muutuste 
samaaegset hindamist; (ii) soo, vanuse, KMI ja haiguse faasi arvestamist; 
(iii) OA röntgenoloogiliste tunnuste – osteofüütide ja LVK – eraldi käsitle-
mist kuna patofüsioloogiliselt iseloomustavad need haiguse erinevaid 
staadiume ning on peegeldatavad erinevate biomarkerite poolt; ning (iv) 
rohkem kui kahe jälgimispunkti kasutamist longitudinaalsetes uuringutes 
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